

AD \_\_\_\_\_

Award Number: DAMD17-98-1-8340

TITLE: HET is a Novel Tumor Suppressor Gene in Human Breast Cancer

PRINCIPAL INVESTIGATOR: Steffi Oesterreich, Ph.D.

CONTRACTING ORGANIZATION: Baylor College of Medicine  
Houston, Texas 77030

REPORT DATE: October 2001

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20020909 025

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 2001		3. REPORT TYPE AND DATES COVERED Final (1 Oct 98 - 30 Sep 01)
4. TITLE AND SUBTITLE HET is a Novel Tumor Suppressor Gene in Human Breast Cancer			5. FUNDING NUMBERS DAMD17-98-1-8340	
6. AUTHOR(S) Steffi Oesterreich, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Baylor College of Medicine Houston, Texas 77030  E-Mail: steffi@bcm.tmc.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES Report contains color				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words)  We have discovered that the nuclear matrix protein HET/SAFB maps to a chromosomal locus on 19p13 which displays very high loss of heterozygosity (LOH). LOH are hallmarks of tumor suppressor genes, and thus we studied whether HET/SAFB could function as a tumor suppressor gene. Over the last three years we have generated data, which not only support our hypothesis but also allowed us to get further funding to extend our studies. We have confirmed the high LOH rates in a second independent LOH study using microdissected breast tumors. Again, the LOH rates were unusually high (70-80%). We have identified point mutations in the HET/SAFB gene in breast cancer cell lines as well as in tumors but not in the adjacent normal tissue. The reintroduction of a mutated SAFB into cell lines leads to phenotypical changes observed in breast tumors. Furthermore, SAFB expression in breast tumors is associated with aneuploidy, suggesting a possible involvement in chromosomal integrity. Finally, we have recently begun to generate mice models, which will help us to definitely prove that SAFB is involved in tumorigenesis.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 38	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

**TABLE OF CONTENTS**

<b>Front Cover.....</b>	<b>Page 1</b>
<b>Standard Form.....</b>	<b>Page 2</b>
<b>Table of Contents.....</b>	<b>Page 3</b>
<b>Introduction.....</b>	<b>Page 4</b>
<b>Body</b>	
<b>Experimental Methods and Procedures.....</b>	<b>Page 4</b>
<b>Results.....</b>	<b>Page 4</b>
<b>Discussion.....</b>	<b>Page 6</b>
<b>Key Research Accomplishments.....</b>	<b>Page 7</b>
<b>Reportable Outcomes.....</b>	<b>Page 7</b>
<b>Conclusions.....</b>	<b>Page 8</b>
<b>References.....</b>	<b>Page 8</b>
<b>Appendices.....</b>	<b>Page 10</b>

## INTRODUCTION

As presented in our original grant proposal, we have evidence that the nuclear matrix protein HET might represent an important tumor suppressor gene in human breast cancer: 1. Overexpression of HET inhibited growth. 2. It was negatively associated with S-phase fraction in breast tumors, and 16% of breast tumors did not express HET. 3. Western Blot analysis in breast tumors led to the detection of smaller products, presumably representing truncated HET proteins. 4. HET maps to a locus on chromosome 19p13 where we detected an unusually high rate of loss of heterozygosity (LOH). Excited by this preliminary observation, we proposed to examine whether HET is the tumor suppressor gene at 19p13. The proposed analyses included further LOH analysis, mutational studies, as well as functional studies of the protein in breast cancer cells.

## BODY


### Experimental Methods and Procedures

All experiments and procedures were carried out as described in the manuscripts resulting from this award (see later).

### Results

#### A) High Rates of Loss of Heterozygosity on Chromosome 19p13 in Breast Tumors

We were able to reproduce our findings of high rates of LOH in a second independent study – again we found LOH rates averaging 78% [1] (Fig.1). Two other studies report high rates of LOH at this locus in tumors and metastases, respectively, arising from hormone-responsive tissues. Wang et al described loss at 19p13.3 in ovarian tumors [2], and Sobottka et al. reported LOH in brain metastases arising from primary breast cancers [3]. Furthermore, Dr. Joe Gray at UCSF has recently done a large CGH study using breast tumors, and again found that 19p13 displays very high loss (personal communication). The peak of loss is at the SAFB locus at the D19S216 marker.




**Fig. 1: High rate of LOH at chromosome 19p13.** Top panel: Rates of LOH are shown in relation to used polymorphic markers and their location on radiation hybrid map. Bottom panel: LOH (filled circle), no LOH (empty circle), non informative (striped circle). LOH rates are shown at four adjacent polymorphic markers.



## B) SAFB is mutated in Breast Cancer

We have performed SSCP analysis in order to identify SAFB mutations in breast cancer specimens. Despite intensive and concentrated efforts we were unable to get consistent results due to the frequent appearance of multiple bands. We have recently identified the reason for these problems – SAFB is part of a family of highly related genes. We have identified a second gene (from now on called SAFB2) which maps adjacent to HET/SAFB (SAFB1) at the high LOH locus. We believe that the genes were duplicated during evolution – they have similar but

also divergent functions (Townson et al. manuscript in preparation). We are currently performing a sequencing study using primer pairs specific for either SAFB1 or SAFB2.



**Fig.2. SAFB1 and SAFB2 are highly homologous proteins.** A) The two genes are located in tandem orientation on chromosome 19p13, separated by less than 500bp. B) The two genes have regions of very high homology (e.g. SAF-Box) and of very low homology (e.g. NLS). SAF-Box, Scaffold Attachment Factor Box; RRM, RNA Recognition Motif; HLH, Helix Loop Helix; NLS, Nuclear Localization Signal; Glu/Arg/Glu repeats, function unknown.

However, we were able to identify specific mutations in SAFB1 in both breast cancer cell lines as well as in breast tumors. These mutations were not found in the adjacent normal tissue. Although some mutations are conserved amino acid substitutions the effects might be dramatic. For example, Ala/Val mutations in MECP2 are important in Rett Syndrome patients [4]. We have begun to analyze the phenotype of the mutations. Therefore we reintroduced the

point mutation into the SAFB1 plasmid using the Quick Change Site Directed Mutagenesis kit (results are discussed below).

Cell Line/ Case <sup>2</sup>	Codon	Nucleotide Change	Amino Acid Change
MCF-7/MG	1891	aag/agg	Lys/Arg
T47D	1391	ctc/ccg	Leu/Pro
MDA-MB-468	265	aat/gat	Asn/Asp
Tumor#48	1186	gct/gtt	Ala/Val
Tumor#30	1838	gcc/ggc	Ala/Gly

**Fig. 3. HET/SAFB is mutated in breast cancer cell lines and breast tumors.** RNA was isolated, reverse transcribed and sequenced using primers as described in Oesterreich et al [1]

## C) Reintroduction of mutated SAFB results in increased proliferation and increased apoptosis

Using the Quick Change Kit we introduced the Asn/Asp (265) mutation into the GFP-HET/SAFB plasmid, and transiently transfected various cell lines (MCF-7, 293). Transfected cells were sorted via FACS, and cell cycle distribution was analyzed. We observed that in contrast to wildtype HET/SAFB that results in a significant decrease in S-phase, the mutated HET/SAFB gene did not result in a decrease in S-phase. Furthermore we detected a large

percentage of apoptotic cells. Although seemingly counterintuitive, similar observations have been made in breast cancer in which the rate of apoptosis is increased in parallel to an increase in proliferation. We are currently generating additional mutants, and will further our functional studies using those.

Although the mechanism of tumor suppression was not the major focus on the grant we have begun to address this question. We have discovered that SAFB is an estrogen receptor (ER) corepressor [5], and as such its loss could result in increased proliferation in ER+ tumors.

We are currently studying SAFB as an ER corepressor, the mechanism of repression and the biological significance. I have recently submitted an R01 application towards this goal. We do not know at this point in time whether there are additional functions of SAFB, which could be important for its tumor suppressing activities. We do however expect that SAFB might play a role in chromatin integrity since its expression is highly correlated with aneuploidy in breast tumors [6]. Further studies are needed to decipher this potential role.

## DISCUSSION

We discovered that the chromosomal locus 19p13.3 displays very high LOH rates in human breast cancer. We have also found that the nuclear matrix protein HET/SAFB and a second highly related gene (from now on termed SAFB1 and SAFB2) are mapped to this region, and we have identified mutations in these genes. Preliminary studies indicated that one of those mutations results in a high proliferative and apoptotic phenotype in breast cancer cell lines. Final in vivo experiments using SAFB knock out mice are underway to prove that inactivation of SAFB results in tumor development and progression.

It is however important to point out that these data do not allow to conclude that there is no other candidate tumor suppressor gene. To address this question we are currently making CGH arrays using overlapping BAC clones from the high LOH area (Fig. 4). These studies are done in collaboration with Dr. Joe Gray from UCSF. Furthermore we are generating "custom cDNA

arrays" using cDNAs from the same area. The areas will be hybridized with DNA and RNA from LOH-positive and -negative tumors, and we hope to be able to definitely exclude or include other candidate genes.




Fig. 4: Plan of array studies to study whether additional candidates are involved in 19p13LOH-driven breast cancer development and progression.

In summary we have generated significant data, and were also able to receive further funding to keep these exiting studies going. We hope that our results will help to improve breast cancer diagnosis and treatment.

## **KEY RESEARCH ACCOMPLISHMENTS**

- We were the first to discover a locus on chromosome 19p13, which displays extremely high LOH in breast tumors.
- We have detected mutations in a candidate gene HET/SAFB, and preliminary studies indicate that these mutations play a role in altered proliferation and apoptosis.
- We have found that HET/SAFB functions as an estrogen receptor corepressor.

## **REPORTABLE OUTCOMES**

### Publications:

1. **Oesterreich S**, Zhang Q, Hopp T, Fuqua SAW, Michaelis M, Zhao HH, Davie JR, Osborne CK, Lee AV. Estrogen Receptor bound to the antiestrogen Tamoxifen strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of estrogen receptor-mediated transactivation. Mol. Endo. 14, 369-381, 2000.
2. Steven M. Townson, Toby Sullivan, QingPing Zhang, Gary M. Clark, C. Kent Osborne, Adrian V. Lee, and **Steffi Oesterreich**. HET/SAF-B Overexpression Causes Growth Arrest and Multinuclearity and Is Associated with Aneuploidy in Human Breast Cancer. Clinical Can Res 6, 3788-3796, 2000.
3. **Oesterreich S**, D. Craig Allred, Syed Mohsin, Adrian V. Lee, C. Kent Osborne, Peter O'Connell. Loss of Heterozygosity at the HET/SAF-B Locus on Chromosome 19p13 in Human Breast Cancer. Br. J. Cancer; 84(4):493-498 2001

### Oral Presentation:

SPORE Investigator Meeting, Washington DC, 7/1999  
Flemish Gynecological Society Meeting, Brussels, 12/1999  
DOD Breast Cancer Research Program Meeting Era of Hope, Atlanta, 6/2000  
Breast Cancer Think Tank Meetings (1/1999, 1/2000, and 1/2001, and 1/2002)

### Funding:

DOD Concept Award: Rapid Screen for Tumor Suppressor Genes on Chromosome 19p13  
\$50,000, 07/01/2000-06/30/2001

Postdoctoral Fellowship for Dr. M. Ivanova (DOD): Is HET/SAF-B a tumor suppressor gene in human breast cancer. Generation of a mouse model. \$149, 989 total costs, 7/2001-6/2004

Postdoctoral Fellowship for Dr. Steven Townson (DOD): Mechanism of HET/SAFB Co-repression of Estrogen Receptor-mediated transcriptional activation. \$150,000, 7/20001-6/2004

Chao Award: Is HET/SAF-B a tumor suppressor gene in breast cancer? (Supply Money for Generation of Knock-out mice). \$50,000. 7/1/00-6/30/02

Employment opportunity:

I accepted a new position as an Assistant Professor at Baylor College of Medicine (BCM) during year 1 of the award. This relocation has had a very positive impact of my research productivity.

**CONCLUSIONS**

We have made significant contribution to the area of breast cancer research since we have discovered that a nuclear matrix protein HET/SAFB is very likely to function as a tumor suppressor gene in an extremely high LOH area on chromosome 19p13. The funding through the DOD IDEA mechanism allowed us to study this "high risk" project, we made significant progress, and have now new funding to continue our studies.

**REFERENCE:**

1. Oesterreich, S., et al., High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer. *Br J Cancer*, 2001. **84**(4): p. 493-8.
2. Wang, Z.J., et al., Allele loss and mutation screen at the Peutz-Jeghers (LKB1) locus (19p13.3) in sporadic ovarian tumours. *Br J Cancer*, 1999. **80**(1-2): p. 70-2.
3. Sobottka, S.B., et al., Frequent loss of heterozygosity at the 19p13.3 locus without LKB1/STK11 mutations in human carcinoma metastases to the brain. *J Neurooncol*, 2000. **49**(3): p. 187-95.
4. Amir, R.E. and H.Y. Zoghbi, Rett syndrome: methyl-CpG-binding protein 2 mutations and phenotype-genotype correlations. *Am J Med Genet*, 2000. **97**(2): p. 147-52.
5. Oesterreich, S., et al., Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. *Mol Endocrinol*, 2000. **14**(3): p. 369-81.
6. Townson, S.M., et al., HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer [In Process Citation]. *Clin Cancer Res*, 2000. **6**(9): p. 3788-96.

Personnel paid on the grant:

Qingping Zhang, Research Technician (100% effort years 1 and 2)

Peter O'Connell, Ph.D., Professor (3% effort, years 1 through 3)

Wanleng Deng, Ph.D., Research Associate (100% effort, year 3)

## APPENDICES

1. **Oesterreich S** et al.: Estrogen Receptor bound to the antiestrogen Tamoxifen strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of estrogen receptor-mediated transactivation. *Mol. Endo.* 14, 369-381, 2000.
2. Townson et al.: HET/SAF-B Overexpression Causes Growth Arrest and Multinuclearity and Is Associated with Aneuploidy in Human Breast Cancer. *Clinical Can Res* 6, 3788-3796, 2000.
3. **Oesterreich S** et al.: Loss of Heterozygosity at the HET/SAF-B Locus on Chromosome 19p13 in Human Breast Cancer. ; *Br. J. Cancer* 84(4):493-498 2001

## High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer

S Oesterreich<sup>1</sup>, DC Allred<sup>1,2</sup>, SK Mohsin<sup>1,2</sup>, Q Zhang<sup>1</sup>, H Wong<sup>1</sup>, AV Lee<sup>1</sup>, CK Osborne<sup>1</sup> and P O'Connell<sup>1</sup>

<sup>1</sup>Breast Center, Department of Medicine, and Department of Molecular and Cellular Biology; <sup>2</sup>Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030

**Summary** We have recently discovered that the nuclear matrix protein SAFB is an oestrogen receptor corepressor. Since it has become clear that many steroid receptor cofactors play important roles in breast tumorigenesis, we investigated whether SAFB could also be involved in breast cancer. To address this question, the gene locus was examined for structural alterations in breast cancer tissue. Laser capture microdissection was used for isolating DNA from paired primary breast tumour and normal tissue specimens, and the loss of heterozygosity (LOH) at chromosome 19p13.2–3 was determined by use of microsatellite markers. LOH was detected at the marker D19S216, which colocalizes with the SAFB locus, in specimens from 29 (78.4%) of 37 informative patients. The peak LOH rate occurred at D19S216 near the SAFB locus, with LOH frequencies ranging from 21.6% to 47.2% at other markers. The finding of a very high LOH rate at the marker D19S216 strongly indicates the presence of a breast tumour-suppressor gene locus. While preliminary findings of mutations in SAFB suggest that this indeed may be a promising candidate, other potential candidate genes are located at this locus. © 2001 Cancer Research Campaign <http://www.bjcancer.com>

**Keywords:** loss of heterozygosity; chromosome 19p13; breast cancer; SAFB; tumour suppressor gene; mutation

The oestrogen receptor (ER) is a nuclear steroid receptor that upon activation by its ligands (e.g. oestrogen) initiates a cascade of events resulting in increased cellular proliferation in its target tissues (Warner et al, 1999). Since oestrogen is one of the most potent mitogens for breast cancer cells, it is no surprise that ER is the most important target for endocrine therapy of breast cancer (Osborne, 1998). Recently, a number of factors which regulate nuclear hormone receptor activity have been identified. Cofactors capable of increasing receptor action, termed coactivators, include transcriptional intermediary factor 1 (TIF1), nuclear receptor interacting protein (NRIP1), nuclear receptor coactivator 2 (TIF2), steroid receptor coactivator 1 (SRC1), amplified in breast cancer 1 (AIB1), the cyclic AMP (cAMP)-response element binding protein (CREB) binding protein (CBP) (Glass et al, 1997; Shibata et al, 1997) and many more. The family of corepressors (negative regulators) of ER is smaller; the best characterized ones being the nuclear receptor corepressor (N-CoR) (Horlein et al, 1995; Shibata et al, 1997) the silencing mediator of retinoid and thyroid receptors (SMRT) (Chen and Evans, 1995; Sande and Privalsky, 1996) and the repressor of ER activity (REA) (Montano et al, 1999). The overexpression of coactivators or the loss of corepressors could lead to deregulation of oestrogen-dependent pathways related to mammary epithelial cell proliferation, and thus to breast tumorigenesis. And indeed, some of the ER cofactors have recently been characterized as playing major roles in breast tumorigenesis (Horlein et al, 1995; Anzick et al, 1997; Shibata et al, 1997). The ER coactivator AIB1 was cloned during a search on the long arm of chromosome 20 for genes whose expression and copy number are

elevated in human breast cancer, and subsequent analysis in 105 breast tumour specimens confirmed its overexpression (Anzick et al, 1997). Interestingly, the breast/ovarian tumour suppressor gene *BRCA1* has recently been characterized as an ER corepressor (Fan, 1999) again suggesting that ER coregulators are crucial in breast tumorigenesis. Thus, it might be expected that other ER coactivators and corepressors might play similar important roles in breast cancer development and progression.

The nuclear matrix protein SAFB (Renz, 1996; Oesterreich, 1997) has been shown to be an ER corepressor (Oesterreich et al, 2000). ER and SAFB interact in in-vitro binding assays (Glutathione-S-Transferase [GST]-pulldown assays) and in cell lines (co-immunoprecipitation experiments). In cell lines, there is binding of SAFB to ER in the presence or absence of oestradiol; however, binding is significantly increased by the antioestrogen tamoxifen. Overexpression of SAFB results in repression of oestrogen-mediated transactivation of gene expression by the ER. Furthermore, as a result of SAFB overexpression, the antagonist activity of tamoxifen on ER can be enhanced, and the agonist activity of tamoxifen can be inhibited.

These results led us to investigate whether the ER corepressor SAFB could also be involved in breast tumorigenesis. Towards this goal we analysed whether the chromosomal locus for SAFB is a frequent target for chromosomal aberrations, i.e., allelic deletion. Allelic deletion manifested as loss of heterozygosity (LOH) at polymorphic loci is recognized as a hallmark for genes involved in tumour suppression; thus, high LOH at the SAFB locus would suggest that this recently identified ER cofactor could play an important role in breast tumour suppression. In the present study we proposed to study human breast cancer specimens for the rate of LOH at different markers that colocalize with or are adjacent to the SAFB locus on chromosome 19p13. To strengthen our hypothesis we also performed mutational analysis of SAFB in both LOH-positive tumours as well as in breast cancer cell lines.

Received 26 June 2000

Revised 23 October 2000

Accepted 8 November 2000

Correspondence to: P O'Connell

## METHODS

### Patients, tissues, and microdissection

The 57 patients whose tissue was evaluated in this study had primary breast cancer; their archival paraffin-embedded tissues were used for the analysis. For 52 of the 57 patients, a single paraffin section yielded sufficient normal tissue (terminal duct lobular unit) and primary cancer. For 5 patients, normal lymph node tissues were recovered from separate blocks. Single 5 µm sections were cut from the selected blocks, mounted on glass slides, deparaffinized, and lightly counterstained with nuclear fast red to guide laser capture microdissection (LCM) of cells using an LCM instrument (Pixcell by Arcturus Engineering) (Emmert-Buck et al, 1996; Simone et al, 1998). Briefly, a transparent thermoplastic film (ethylene vinyl acetate polymer) was placed over the section on the slides. A laser directed through the microscope optics was activated, causing the thermoplastic film to melt and fuse with the underlying targeted cells. The selected cells remained adherent to the film when it was removed from the slide. An average of approximately 1000 cells (about 100 cell clusters of 10 cells each) was harvested from each tissue sample.

### LOH analysis

LOH analysis was performed as recently described (O'Connell et al, 1999). Briefly, DNA was prepared by a modification of the method of Wright and Manos (Wright and Manos, 1990). The embedded cells were incubated for 18–20 hours at 37°C in 60 µl of a lysis buffer that contained 10 mM Tris-HCl (pH 8.5), 1 mM EDTA, 0.045% NP-40, 0.045% Tween-20, and 1.0 mg ml<sup>-1</sup> proteinase K. The proteinase was then inactivated at 95°C for 10 minutes. PCR and gel electrophoresis was performed as described previously by us (O'Connell et al, 1999). Samples were evaluated for LOH using the microsatellite markers D19S216, D19S413, D19S591 and D19S883. The primer pairs were obtained from Research Genetics, Inc. (Birmingham, AL). Mapping data were obtained from the Genome DataBase (GDBTM) at Johns Hopkins University (Fasman et al, 1997; Talbot and Cutichia, 1999). The intensity ratios of bands in electrophoretic gels representing different marker alleles in the DNA obtained from paired normal and breast cancer tissues were calculated from digitized data collected with a storage phosphor device and analysed with the Molecular Dynamics ImageQuant software package (Molecular Dynamics, Sunnyvale, CA). LOH was considered positive when the proportion ((tumour allele 1/tumour allele 2)/(normal allele 1/normal allele 2)) equalled either less than 0.71 (tumour allele 1 LOH) or greater than 1.4 (tumour allele 2 LOH).

### Mutational analysis

RNA from MCF-7/MG (Oesterreich et al, 1993), T47D, and MDA-MB-468 breast cancer cell lines was isolated using Qiagen RNeasy kit (Valencia, CA) according to the manufacturer's instructions. First strand SAFB cDNAs were synthesized in two parts (a 5' and 3' segment) by reverse transcriptase (RT)-PCR using Avian Myeloblastosis Virus (AMV) RT (Promega, Madison, WI) on 1 µg of total RNA as previously described (Wang et al, 1999). The primers for RT were 5'-GAGTCTCTTGACTTCCGAGGC-3' (for 5' fragment) and 5'-TCCAAGTACTCAGTAGCGGCG-3' (for 3' fragment). Multiple PCR primers were

designed to amplify overlapping regions covering the total cDNA (see footnotes for Table 2). The amplified PCR products were cloned using a TA cloning kit (Invitrogen, Carlsbad, CA), and DNA was isolated and sequenced from at least two clones using Quiaprep Miniprep kit (Quiagen, Valencia, CA).

To analyse the genomic DNA from the LOH-positive tumours, we have started mapping the exon/intron structure of the human SAFB gene by PCR and sequencing. So far we have identified 10 exons, and we designed primer pairs to partially amplify three exons (1F: 5'-ATGGCGAGAGGACGGACT-3' and 1R (intronic): 5'-gogctctgtctctaaactgagaa-3', product size = 271 bp; QP1F: 5'-GACTCTGTCCAGGCCTAGGTGATTC-3' and QP1R: 5'-GCTTCATCCAACACACTGATATCC-3', product size 401 bp; QP6F: 5'-GAGCTTCCAAAAGCCAGGATCGC-3' and QP6R: 5'-CGCTCCTGCTCATAGCGCAGTT-3', product size = 364 bp). We analysed 11 tumours with 1F/R, 15 tumours with QP1F/R, and 2 tumours with QP6F/R. The PCR products were cleaned using Quiaprep PCR purification kit (Quiagen), and directly sequenced. The PCR was performed twice, and the product sequenced from both orientations.

### Sequencing

The sequence of cDNA was determined using an Applied Biosystems model 310 genetic analyser.

### Statistical analysis

The confidence intervals were calculated with the expression  $1.96 \sqrt{P \times (1-P)/i}$  where  $p$  = the LOH frequency and  $i$  = number of informative patients (Dawson Saunders and Trapp, 1994).

## RESULTS

We had previously assigned SAFB to chromosome 19, band p13.2–13.3 by fluorescent in situ hybridization (DuPont et al, 1997). This assignment was subsequently confirmed on the chromosome 19 radiation hybrid map (Deloukas et al, 1998), where SAFB is positioned at 34.7 cRays. As can be seen in Table 1, additional markers and genes have been positioned on chromosome 19p by a combination of FISH, genetic linkage mapping (in centimorgans or cM), and/or radiation hybrid mapping (in centirays or cR). Based on the genetic and physical mapping of this region, 1 cM approximates 120 kilobasepairs (kb) and 1 cR approximates 90 kb on this map. The polymorphic marker D19S216 has been placed on both maps (20.1 cM, 35.9 cRays), so that HET-SAF-B maps in the D19S591-D19S216 interval just proximal to D19S216. This region was tested for LOH using D19S216 and a series of additional markers spanning the chromosome band 19p13, namely, D19S883 (5.5 cM), D19S591 (9.8 cM), D19S216 (20.1 cM), and D19S413 (31.3 cM); which span 3.4 megabasepairs of DNA (Table 1). LOH studies were carried out by comparison of normal and primary breast cancer tissues from 57 patients. 3 of the specimens showed evidence of microsatellite instability and were excluded from further analysis. The results of this LOH study are shown in Table 2. Marker D19S216 near SAFB showed the highest rate of LOH (78%). Figure 1A shows a representative example of an LOH, and Figure 1B summarizes the data from the subset of 25 D19S216-informative patients with interstitial LOH events. An additional 12 patients (not presented) either showed no LOH, or showed LOH for all markers. These breakpoints can map



**Table 1** Markers and breast cancer candidate genes in 19p13.3

Marker <sup>a</sup>	Description	Genetic distance (cM) <sup>b</sup>	RH distance (cR) <sup>c</sup>	Megabases <sup>d</sup>
APCL	Adenomatous polyposis coli-like	—	6.1	16.6+/-4.4
D19S883	Microsatellite AFMa299yc1	5.5	22 <sup>a</sup>	15.5+/-0.0
GADD45B	Growth arrest- and DNA damage-inducible gene GADD45, beta	—	23.4	—
D19S591	Microsatellite CHLC.GATA44F10	9.84	27 <sup>a</sup>	15.9+/-0.0
CDC34	Cell division cycle 34	—	—	16.6+/-4.4
SH3GL1	SH3domain, GRB2-like 1	—	32.74	16.6+/-4.4
RANB3	RAN-binding protein 3	—	33.94	16.6+/-4.4
SAFB	Scaffold attachment factor B	—	34.66	19.4+/-7.2
D19S216	Microsatellite AFM164zb8	20.01	35.88	16.7+/-0.0
TRIP10	Thyroid hormone receptor interactor 10	—	40.66	—
INSR	Insulin receptor	25.17	41.55	17.8 +/-0.0
D19S413	Microsatellite AFM292wd9	32.39	59.76	18.9+/-0.0

<sup>a</sup>Genome Database nomenclature (Talbot and Cuticchia, 1999). <sup>b</sup>Distances in centimorgans (cM) from the Marshfield Chromosome 19 Sex-Averaged linkage map (Broman et al, 1998). <sup>c</sup>Distances in centirays (cR) from the International Radiation Hybrid Mapping Consortium (GeneMap'99) (Deloukas et al, 1998).

<sup>d</sup>Distances from the Genome Database (Talbot and Cuticchia, 1999). <sup>e</sup>RH distances inferred based on International Radiation Hybrid Mapping Consortium (GeneMap'99) (Deloukas et al, 1998).

**Table 2** Loss of heterozygosity<sup>a</sup> frequencies for genetic markers on chromosome 19p13.3 in breast cancer patients

Marker	Location (centimorgans)	LOH frequency = no. of patients with LOH / no. of informative patients (%); (95% confidence interval) <sup>b</sup>
D19S883	5.5	8/37 (21.6); (8.3–34.9)
D19S591	9.8	17/36 (47.2); (30.9–63.5)
D19S216	20.1	29/37 (78.4); (65.1–91.7)
D19S413	31.2	11/35 (31.4); (16.0–46.8)

Heterozygosity is the presence of two different alleles for the genetic marker; loss of heterozygosity (LOH) is present when tumour/normal allele intensities calculated as below vary from those seen in normal tissue: LOH is present when ((tumour allele 1/tumour allele 2)/(normal allele 1/normal allele 2)) ratio is either equal to or less than 0.71 for tumour allele 1 or is equal to or greater than 1.4 for tumour allele 2. <sup>b</sup>The number of LOH events observed divided by the subset of those patients out of the 54 tested whose normal DNA sample was heterozygous for the genetic marker (informative cases). LOH events cannot be detected in a patient whose normal DNA is homozygous for the genetic marker tested. The confidence interval is calculated with the expression  $1.96 \sqrt{P \times (1-P)/i}$ , where  $p$  = the LOH frequency and  $i$  = number of informative patients (19).

the smallest region of overlap for the LOH region(s). The majority of the patients show LOH events in the 3 megabasepair region spanning D19S591–D19S216. 4 patients (numbers 96, 179, 1086 and 1094) showed LOH events but remained heterozygous for D19S216, indicating the tumour suppressor is distal of D19S216 (i.e., near SAFB). LOH events in 4 other patients (numbers 190, 207, 613 and 742) lost only D19S216, and patient 810 lost DNA sequences including D19S216 and D19S413. No D19S216-informative tumours exclusively lost D19S413. We also did not detect any homozygous deletion. These data suggest that the interval between D19S591–D19S216 including SAFB harbours a tumour suppressor gene important in human breast cancer. To support our hypothesis, mutational analysis of the remaining SAFB allele was performed in the LOH-positive tumours. SAFB cDNA was also sequenced in 3 breast cancer cell lines.


First we analysed transcripts from MCF-7/MG, T47D and MDA-MB-468 breast cancer cell lines. RT-PCR amplification followed by subcloning of the PCR product and sequencing led to

the identification of 3 point mutations changing amino acids (Table 3). The presence of these mutations was confirmed by direct sequencing of genomic DNA from the cell lines (data not shown). To further search for mutations, we PCR-amplified genomic DNA from the nondeleted allele in the LOH-positive tumours, and the results of this study are shown in Table 3. Two point mutations were identified which resulted in amino acid changes, and which were not detected in the adjacent normal tissue. Thus, evidence from sequence analysis of SAFB suggests that the gene indeed is a promising candidate for a breast cancer tumour suppressor gene at the high LOH locus on chromosome 19p13.

## DISCUSSION

Several groups have performed LOH studies on chromosome 19p13. Kerangueven et al [Kerangueven, 1997] identified D19S216 as a marker with consistent loss (20–30% of patients) in breast cancer using genomic DNA isolated from whole breast tumours. Bignell et al (1998) also performed an LOH study on chromosome 19p13.3, with the goal of analysing chromosomal loss of the LKB1 gene (the serine/threonine kinase LKB1 is mutated in patients with Peutz-Jeghers Syndrome, resulting in intestinal hamartomas associated with an elevated risk for cancer). They used the LKB-linked marker D19S565, which co-localizes with D19S883. The Bignell study detected LOH in 7.5% of informative breast cancer specimens, as compared with 21.6% in our study.

It is difficult to compare the LOH rates from our present LCM-based study to those of previous reports, since only a few studies using LCM material have been published. For instance Bignell et al saw 7.5% (3 of 40) LOH with D19S565 using whole tissue genomic DNA while we found 21.6% (8 of 37) using LCM material. Though part of this difference might simply reflect the small number of samples, we have previously seen that LCM enriches for tumour cells and thus always results in a higher LOH rate. As an example, we found 53% LOH (32 of 60) at D19S216 using an essentially identical set of manually microdissected archival paraffin-embedded primary breast cancer specimens (data not shown), but saw 78% LOH (29 of 37) using LCM. Brown et al (1999) also noted elevated LOH rates at 8p12–22 in ovarian



**Figure 1** Loss of heterozygosity (LOH) profiles in the D19S216-SAFB region. (A) DNA from microdissected tumour samples (T) and normal (N) corresponding material was analysed by PCR using the microsatellite marker D19S216. Left: no LOH, Middle: LOH – loss of allele 1; right: LOH – loss of allele 2. (B) Bottom: An idiogram of chromosome 19p13.11–p13.3 detailing the region of interest and the locations of the markers tested in centimorgans (cM). Top: The LOH profiles of 25 selected patients (patient numbers: 12 to 1112) informative for D19S216 with interstitial breakpoints. Data for breast cancer patient numbers 12–1112 are shown horizontally for each marker. Filled circles denote patients with LOH, open circles denote heterozygous patients (no LOH), and hatched circles show non-informative patients

cancers when comparing LCM-based LOH rates with those determined in previous allelotyping studies. Tamura et al (1994) noted 35% LOH at the retinoblastoma (RB) locus on chromosome 13 from whole tumours, but a 59% rate of RB locus LOH when the tumour cells were enriched by flow sorting. We have also determined a rate of 56% LOH at the RB locus (data not shown) in our LCM-based breast cancer studies.

Our rationale for this study was that the ER corepressor SAFB might represent a new tumour suppressor gene, and our present

**Table 3** SAFB cDNA and genomic DNA mutations in breast cancer cell lines and LOH-positive tumours

Cell line/Case <sup>a</sup>	Codon	Nucleotide change	Amino acid change
MCF-7/MG <sup>b</sup>	1891	AAG/AGG	Lys/Arg
T47D <sup>c</sup>	1391	CTC/CCC	Leu/Pro
MDA-MB-468 <sup>d</sup>	265	AAT/GAT	Asn/Asp
Tumour #48 <sup>e</sup>	1186	GCT/GTT	Ala/Val
Tumour #30 <sup>e</sup>	1838	GCC/GGC	Ala/Gly

<sup>a</sup>The complete cDNA from 3 breast cancer cell lines was analysed. The sequence analysis of the normal/tumour DNA covers 10%, 14% and 13% of the SAFB exon sequence from 11, 15 and 2 cases, respectively.

<sup>b</sup>The 3' first strand cDNA was amplified using forward primer 5'-GGGGTGCC-TGTGATTAGTGT-3' and reverse primer 5'-TCAGAATGGTAGCGCTCATCC-3'.

<sup>c</sup>The 3' first strand cDNA was amplified using forward primer 5'-TGGACTCTC-TTCTACACCAGAGC-3' and reverse primer 5'-GTCAGTGTGCTCGACTT-CTCC-3'. <sup>d</sup>The 5' first strand cDNA was amplified using forward primer 5'-AATGGCGGAGACTCTGTCAGGC-3' and reverse primer 5'-ACAGGCTGTCTGCCTTGCTC-3'.

<sup>e</sup>For tumours #48 and #30, genomic DNA from microdissected tumour and adjacent normal tissue was amplified using primer pairs 1F/1R and QP6F/6R (see Methods).

finding would certainly support this hypothesis. LOH frequency at D19S591-SAFB-D19S216 region is among the highest yet measured in breast cancer, and mutational analysis of the SAFB gene in both human breast cancer cell lines and tumours revealed point mutations resulting in amino acid changes. Our sequence analysis so far examined approximately 13% of the SAFB exon sequence from 28 tumours. Although further sequence analysis might lead to the identification of additional mutations in those tumours, our preliminary results indicate that the mutation rate is not very high. It is possible that other epigenetic changes might play a role in inactivating SAFB. Inactivations of tumour suppressor genes through methylation (Merlo et al, 1995; Esteller et al, 2000; Simpson et al, 2000), through altered ubiquitin degradation (Pagano et al, 1995; Tam et al, 1997; Scheffner, 1998; Zaika et al, 1999), and through mislocalization (Chen et al, 1995) are increasingly recognized as alternative inactivating mechanisms. Our own Western blot analyses have demonstrated variations in the abundance of SAFB in breast tumour specimens – in 16% of the tumours (10/61), no SAFB protein was detectable even after prolonged exposure of X-ray films, and in an additional 3% (2/61), SAFB appeared to be truncated (Townson et al, 2000). Thus, other inactivating mechanisms might indeed be involved in loss of SAFB. Recent studies have suggested that haploinsufficiency of some tumour suppressor genes is sufficient for tumorigenesis (Kairouz et al, 1999; Cook and McCaw, 2000).

Despite these observations, we can not exclude that another gene in close proximity to SAFB functions as a tumour suppressor gene in human breast cancer. The 19p13 region studied spans approximately 3 megabasepairs of DNA (see Table 1). A total of 20 known genes and 88 ESTs have been placed in this region

by the International Radiation Hybrid Mapping Consortium (GeneMap'99) (Deloukas et al, 1998). In addition to SAFB, 7 other genes in the region are potentially breast cancer related. APCL, a homologue of the APC tumour suppressor gene, maps near D19S883, which is outside the peak region of LOH at D19S216. Furthermore, APCL expression has been reported to be brain-specific (Nakagawa et al, 1999). GADD45B, a homologue of the growth arrest and DNA damage-inducible GADD45 gene (Sheikh et al, 2000), maps near D19S591, 800 kb from the peak of LOH near D19S216. The thyroid hormone interacting protein (TRIP10) (Lee et al, 1995) and the insulin receptor (INSR) (Morris, 1997) gene appear to map distal of D19S216, and in any case these genes seem better candidates as oncogenes rather than tumour suppressor genes. 3 genes, the GRB2-like SH3 domain containing gene (SH3GL1) (Giachino et al, 1997), the Ras-related nuclear protein-binding protein (RANBP3) (Mueller et al, 1998), and G<sub>2</sub> cell division cycle checkpoint gene (CDC34) (Kaiser et al, 2000), all map to the same interval as SAFB. However, as noted above, SH3GL1 seems a better candidate for an oncogene than tumour suppressor genes. RANBP3 and CDC34 (or an uncharacterized EST) in this region remain potential candidate tumour suppressor genes in addition to SAFB.

Further studies are necessary to extensively characterize this extremely interesting region on chromosome 19p13, and to firmly establish SAFB as a tumour suppressor gene, or to show that a gene other than SAFB is the true classical tumour suppressor gene at this locus.

## ACKNOWLEDGEMENTS

The authors wish to thank Lei Hao, Toby Sullivan, and Jeffrey Chavez for expert technical assistance, and Gary Chamness for critical reading and Susan Hilsenbeck for helpful discussion of this manuscript. This work was supported by US Department of Defense grant DAMD17-98-8340, and PHS grants K01 CA77654, P50-CA58183 and P01-CA30195.

## REFERENCES

- Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM and Meltzer PS (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. *Science* **277**: 965-968
- Bignell GR, Barfoot R, Seal S, Collins N, Warren W and Stratton M (1998) Low frequency of somatic mutations in the LKB1/Peutz-Jeghers Syndrome gene in sporadic breast cancer. *Cancer Research* **58**: 1384-1386
- Broman KW, Murray JC, Sheffield VC, White RL and Weber JL (1998) Comprehensive human genetic maps: individual and sex-specific variation in recombination. *Am J Hum Genet* **63**: 861-869
- Brown MR, Chuaiqui R, Vocke CD, Berchuck A, Middleton LP, Emmert-Buck MR and Kohn EC (1999) Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors. *Gynecol Oncol* **74**: 98-102
- Chen JD and Evans RM (1995) A transcriptional co-repressor that interacts with nuclear hormone receptors. *Nature* **375**: 454-457
- Chen Y, Chen CF, Riley DJ, Allred DC, Chen PL, Von Hoff D, Osborne CK and Lee W (1995) Aberrant subcellular localization of BRCA1 in breast cancer. *Science* **270**: 789-791
- Cook WD and McCaw BJ (2000) Accommodating haploinsufficient tumor suppressor genes in Knudson's model. *Oncogene* **19**: 3434-3438
- Dawson Saunders B and Trapp RG (1994) *Basic and Clinical Biostatistics* 2nd edition. East Norwalk
- Deloukas P, Schuler GD, Gyapay G, Beasley EM, Soderlund C, Rodriguez-Tome P, Hui L, Matise TC, McKusick KB, Beckmann JS, Bentolila S, Bihoreau M, Birren BB, Browne J, Butler A, Castle AB, Chiannikulchai N, Clee C, Day PJ, Dehejia A, Dibling T, Drouot N, Duprat S, Fzames C, Bentley DR and et al. (1998) A physical map of 30,000 human genes. *Science* **282**: 744-746
- DuPont BR, Garcia DK, Sullivan TM, Naylor SL and Oesterreich S (1997) Assignment of SAFB encoding Hsp27 ERE-TATA binding protein (HET)/scaffold attachment factor B (SAF-B) to human chromosome 19 band p13. *Cytogenet Cell Genet* **79**: 284-285
- Emmert-Buck MR, Bonner RF, Smith PD, Chuaiqui RF, Zhuang Z, Goldstein SR, Weiss RA and Liotta LA (1996) Laser capture microdissection [see comments]. *Science* **274**: 998-1001
- Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB and Herman JG (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors [In Process Citation]. *J Natl Cancer Inst* **92**: 564-569
- Fasman KH, Letovsky SI, Li P, Cottingham RW and Kingsbury DT (1997) The GDB Human Genome Database Anno 1997. *Nucleic Acids Res* **25**: 72-81
- Giachino C, Lantelme E, Lanzetti L, Saccone S, Bella Valle G and Migone N (1997) A novel SH3-containing human gene family preferentially expressed in the central nervous system. *Genomics* **41**: 427-434
- Glass CK, Rose DW and Rosenfeld MG (1997) Nuclear receptor coactivators. *Current Opinion in Cell Biology* **2**: 222-232
- Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Soderstrom M, Glass CK and et al. (1995) Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. *Nature* **377**: 397-404
- Kairouz R, Clarke RA, Marr PJ, Watters D, Lavin MF, Kearsley JH and Lee CS (1999) ATM protein synthesis patterns in sporadic breast cancer. *Mol Pathol* **52**: 252-256
- Kaiser P, Flick K, Wittenberg C and Reed SI (2000) Regulation of transcription by ubiquitination without proteolysis: Cdc34/SCF(Met30)-mediated inactivation of the transcription factor Met4. *Cell* **102**: 303-314
- Lee JW, Choi HS, Gyuris J, Brent R and Moore DD (1995) Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor. *Mol Endocrinol* **9**: 243-254
- Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB and Sidransky D (1995) 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers [see comments]. *Nat Med* **1**: 686-692
- Montano MM, Ekena K, Delage-Mourroux R, Chang W, Martini P and Katzenellenbogen BS (1999) An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. *Proc Natl Acad Sci USA* **96**: 6947-6952
- Morris BJ (1997) Insulin receptor gene in hypertension. *Clin Exp Hypertens* **19**: 551-565
- Mueller L, Cordes VC, Bischoff FR and Ponstingl H (1998). Human RanBP3, a group of nuclear RanGTP binding proteins. *FEBS Lett* **427**: 330-336
- Nakagawa H, Koyama K, Monden M and Nakamura Y (1999) Analysis of APCL, a brain-specific adenomatous polyposis coli homologue, for mutations and expression in brain tumors. *Jpn J Cancer Res* **90**: 982-986
- O'Connell P, Fischbach K, Hilsenbeck S, Mohsin SK, Fuqua SA, Clark GM, Osborne CK and Allred DC (1999) Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. *J Natl Cancer Inst* **91**: 1391-1397
- Oesterreich S, Weng C-N, Qiu M, Hilsenbeck SG, Osborne CK and Fuqua SAW (1993) The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. *Cancer Research* **53**: 4443-4448
- Oesterreich S, Zhang Q, Hopp T, Fuqua SA, Michaelis M, Zhao HH, Davie JR, Osborne CK and Lee AV (2000) Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation [In Process Citation]. *Mol Endocrinol* **14**: 369-381
- Osborne CK (1998) Steroid hormone receptors in breast cancer management. *Breast Cancer Res Treat* **51**: 227-238
- Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF and Rolfe M (1995) Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27 [see comments]. *Science* **269**: 682-685
- Sande S and Privalsky ML (1996) Identification of TRACs (T3 receptor-associating cofactors), a family of cofactors that associate with, and modulate the activity of, nuclear hormone receptors. *Molecular Endocrinology* **10**: 813-825
- Scheffner M (1998) Ubiquitin, E6-AP, and their role in p53 inactivation. *Pharmacol Ther* **78**: 129-139
- Sheikh MS, Hollander MC and Fornace AJ Jr. (2000) Role of Gadd45 in apoptosis. *Biochem Pharmacol* **59**: 43-45

- Shibata H, Spencer TE, Onate SA, Jenster G, Tsai SY, Tsai MJ and O'Malley BW (1997) Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. *Recent Progress in Hormone Research* 52: 141–164
- Simone NL, Bonner RF, Gillespie JW, Emmert-Buck MR and Liotta JR (1998) Laser-capture microdissection: opening the microscopic frontier to molecular analysis. *Trends in Genetics* 14: 272–276
- Simpson DJ, Hibberts NA, McNicol AM, Clayton RN and Farrell WE (2000) Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. *Cancer Res* 60: 1211–1216
- Talbot CCJ and Cutichia AJ (1999) Human mapping databases. In: *Current Protocols in Human Genetics*, Vol. 1.13.1–1.13.12. John Wiley & Sons, Inc.
- Tam SW, Theodoras AM and Pagano M (1997) Kip1 degradation via the ubiquitin-proteasome pathway. *Leukemia* 11: 363–366
- Tamura G, Maesawa C, Suzuki Y, Kashiwaba M, Ishida M, Saito K and Satodate R (1994) Improved detection of loss of heterozygosity at retinoblastoma gene locus in human breast carcinoma. *Pathol Int* 44: 34–38
- Townson SM, Sullivan T, Zhang Q, Clark GM, Osborne CK, Lee AV and Oesterreich S (2000) HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer [In Process Citation]. *Clin Cancer Res* 6: 3788–3796
- Wang Z, Cody JD, Leach RJ and O'Connell P (1999) Gene expression patterns in cell lines from patients with 18q-syndrome. *Hum Genet* 104: 467–475
- Warner M, Nilsson S and Gustafsson JA (1999). The estrogen receptor family. *Curr Opin Obstet Gynecol* 11: 249–254
- Wright DK and Manos MM (1990) Sample preparation from paraffin embedded tissues. In: *PCR protocols*, Innes MA, Gelfand DH and Sninsky JJ (eds) pp. 153–158. Academic Press: San Diego
- Zaika A, Marchenko N and Moll UM (1999) Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation. *J Biol Chem* 274: 27474–27480

# Tamoxifen-Bound Estrogen Receptor (ER) Strongly Interacts with the Nuclear Matrix Protein HET/SAF-B, a Novel Inhibitor of ER-Mediated Transactivation

Steffi Oesterreich\*, Qingping Zhang\*, Torsten Hopp\*,  
Suzanne A. W. Fuqua\*, Marten Michaelis, Holly H. Zhao,  
James R. Davie, C. Kent Osborne\*, and Adrian V. Lee\*

Department of Medicine (S.O., Q.Z., T.H., S.A.W.F., M.M., H.H.Z.,  
C.K.O., A.V.L.)

Division of Oncology  
University of Texas Health Science Center  
San Antonio, Texas 78284

Department of Biochemistry and Molecular Biology (J.R.D.)  
University of Manitoba  
Winnipeg, Manitoba, Canada R3E 0W3

The estrogen receptor (ER) is a ligand-dependent transcription factor that acts in a cell- and promoter-specific manner. Evidence suggests that the activity of the ER can be regulated by a number of other stimuli (e.g. growth factors) and that the effects of the ER are modulated by nuclear factors termed coregulators. While the interplay among these factors may in part explain the pleiotropic effects elicited by the ER, there are several other less well described mechanisms of control, such as interactions with the nuclear matrix. Here we report that the nuclear matrix protein/scaffold attachment factor HET/SAF-B is an ER-interacting protein. ER and HET/SAF-B interact in *in vitro* binding assays, with HET binding to both the ER DNA-binding domain and the hinge region. Coimmunoprecipitation experiments reveal that HET/SAF-B and ER associate in cell lines in the presence or absence of estradiol, but binding is increased by the antiestrogen tamoxifen. HET/SAF-B enhances tamoxifen antagonism of estrogen-induced ER-mediated transactivation, but at high concentrations can inhibit both estrogen and tamoxifen-induced ER activity. HET/SAF-B-mediated repression of ER activity is dependent upon interaction with the ER-DBD. While the existence of high-affinity binding sites for the ER in the nuclear matrix has been known for some time, we now provide evidence of a specific nuclear matrix protein binding to the ER. Furthermore, our data showing that

HET/SAF-B binds to ER particularly strongly in the presence of tamoxifen suggests that it may be important for the antagonist effect of tamoxifen. (*Molecular Endocrinology* 14:369-381, 2000)

## INTRODUCTION

The estrogen receptor (ER) is a member of a superfamily of nuclear transcription factors. When the ER binds estrogen it undergoes a conformational change that results in dimerization, binding to specific elements of DNA, and finally altered gene transcription (1, 2). While this model of ER action has held true for the last 30 yr, a more complete understanding has revealed that activation of the ER is extremely complex, with regulation by a diverse set of signals and nuclear factors. ER action can be altered by: 1) interaction with other nuclear transcription factors such as AP1 (3), SP1 (4-6), and members of the basal transcription machinery (1); 2) cross-talk with growth factor systems (7); and 3) associations with nuclear receptor coactivators and corepressors (8).

The existence of cofactors that can regulate the transcriptional activity of nuclear hormone receptors was first suggested by transcriptional squelching between ER and progesterone receptor (9, 10). A number of cofactors capable of increasing hormone receptor action, termed coactivators, have been identified (reviewed in Refs. 8 and 11). The family of corepressors is smaller, the best characterized being nuclear receptor corepressor (N-CoR) (8, 12) and silencing mediator of retinoid and thyroid receptors (SMRT) (13, 14). Recently, a corepressor termed REA, which is specific for

ER, has been identified (15). Many cofactors seem to regulate receptor activity by modulating chromatin structure. Coactivators such as p300/CBP (16, 17), PCAF (18, 19), and SRC-1 (20) have intrinsic histone acetyltransferase activity, which results in the destabilization of nucleosomes, creating a permissive state for promoter activation. In contrast, the corepressors N-CoR (21) and SMRT (22) associate with histone deacetylases, leading to a repressive chromatin state.

Another modulator of hormone action is the nuclear matrix, which is a dynamic structure involved in DNA replication, transcription, repair, and RNA processing (23). A role for the nuclear matrix in hormone receptor action was postulated many years ago (24–28), but only recently have specific nuclear matrix proteins been characterized that directly bind to hormone receptors and modulate their activity (29). Most recently, the glucocorticoid receptor-interacting protein GRIP 120 has been identified as the nuclear matrix protein hnRNP (30).

HET was originally cloned in our laboratory as a nuclear matrix protein binding to the promoter of the estrogen-regulated heat shock protein hsp27 (31). Renz and Fackelmayer (32) cloned the same protein based on its ability to bind to scaffold/matrix attachment regions (S/MAR's), and hence called it scaffold attachment factor B (SAF-B). Scaffold attachment factors are a specific subset of nuclear matrix proteins that are thought to mediate the attachment of chromatin to nuclear protein structures (33, 34). A specific role for scaffold attachment factors in hormone receptor action has not been described.

HET/SAF-B has recently been shown to bind to the C-terminal domain of RNA polymerase II (RNA pol II) and to a subset of serine-/arginine-rich RNA processing factors (SR proteins) (35). This suggests that HET/SAF-B is involved in the formation of a transcriptosomal complex, bringing transcription and pre-mRNA processing together. These macromolecular complexes have previously been shown to be associated with the nuclear matrix (36, 37).

Given the recent identification of nuclear matrix factors in hormone receptor action, we asked whether the nuclear matrix protein HET/SAF-B might be involved in ER action. In this report we describe the *in vitro* and *in vivo* association of ER with HET/SAF-B, with HET/SAF-B binding the ER in both the DBD and the hinge region. The association of ER with HET/SAF-B occurs in the absence of ligand but is increased by the antiestrogen tamoxifen (Tam). HET/SAF-B can enhance the antiestrogenic effect of Tam, but when overexpressed at high levels can also repress both estrogen and Tam agonist activity on the ER. Finally, we have shown that the ER DBD is critical for the repressive activity of HET/SAF-B on ER, as HET/SAF-B does not repress activity of an ER-GAL4DBD chimera and can cause transcriptional repression of an ER DBD fused to a heterologous transcription factor. We are currently performing further studies to identify the mechanism of transcriptional repression and whether this is de-

pendent upon the nuclear matrix properties of HET/SAF-B.

## RESULTS


### HET/SAF-B Binds to the ER

To analyze whether HET/SAF-B could bind to ER, we performed glutathione-S-transferase (GST)-pulldown experiments (Fig. 1). First we incubated *in vitro* transcribed and translated ER with full-length GST-HET/SAF-B bound to glutathione-sepharose beads (Fig. 1A). There was no signal when ER was incubated with GST only, in the absence of hormone or in the presence of estradiol ( $E_2$ ). In contrast, ER interacted with GST-HET/SAF-B in the absence of hormone, in the presence of  $E_2$ , and especially in the presence of Tam. We consistently saw increased binding of ER to HET/SAF-B in the presence of Tam compared with no ligand.

Next we examined the ability of HET/SAF-B to interact with different domains of ER (represented graphically in Fig. 1B) in GST-pulldown assays. The different GST-ER domain fusion proteins were separated on SDS-PAGE and Coomassie stained, to ensure that the input of immobilized GST-fusion proteins was equal (data not shown). We examined HET/SAF-B interaction with the AF1, AF1/DNA-binding domain (DBD), DBD/Hinge, DBD, Hinge, and AF2/Hinge domains. All incubations were performed in the absence of hormone. As shown in Fig. 1C, HET/SAF-B consistently interacted strongly with the DBD/Hinge, AF2/Hinge, and AF1/DBD domains and weakly with the Hinge or DBD only. In contrast, we could not detect an interaction between HET/SAF-B and AF1. Thus, there are at least two HET/SAF-B binding sites in the ER protein, one in the DBD and the other one in the Hinge region. The HET/SAF-B interaction with AF2/Hinge was stronger than the interaction with Hinge only, suggesting that there may be another interaction domain within AF2. Thus, as described for the interaction between other cofactors and steroid receptors (38), HET/SAF-B potentially interacts with multiple regions within ER.

We next asked whether we could detect an interaction between HET/SAF-B and ER within cells. Therefore, we transiently transfected COS-7 cells with expression plasmids for HET/SAF-B and hemagglutinin (HA)-tagged ER. Immunoprecipitation of HET/SAF-B followed by immunoblotting for HA revealed a band with the molecular mass of ER (~68 kDa) that was only seen when cells were transfected with both ER and HET/SAF-B, but not in cells transfected with HET/SAF-B only (Fig. 2A, *left panel*). A similar experiment, but in a reciprocal manner, was performed using an HA-antibody to immunoprecipitate and the HET/SAF-B antibody for immunoblotting. As expected, a band at the molecular mass of HET/SAF-B (~130 kDa) was detected in cells transfected with HET/SAF-B and





**Fig. 1.** HET/SAF-B Directly Interacts with ER *in Vitro* (GST-Pull-Down Experiments)


A, ER was labeled with  $^{35}\text{S}$ -methionine by *in vitro* transcription/translation and tested for interaction with GST alone and GST-HET/SAF-B in the absence of ligands, or in the presence of  $10^{-6}$  M  $\text{E}_2$  or  $10^{-6}$  M Tam (as indicated). The input lane contains 20% input of the *in vitro* transcribed/translated ER. B, Schematic presentation of GST-tagged ER domains. The numbers indicate amino acids in ER's open reading frame. C, HET/SAF-B was labeled with  $^{35}\text{S}$ -methionine by *in vitro* transcription/translation and tested for interaction with GST alone and a number of GST-ER domain fusion proteins (as indicated). The input lane contains 20% input of the *in vitro* transcribed/translated HET/SAF-B.

ER, but not in cells transfected with HET/SAF-B only (Fig. 2A, right panel).

The next set of coimmunoprecipitation experiments was performed to see whether endogenous HET/SAF-B and ER indeed interact and whether this interaction was altered by  $\text{E}_2$  or Tam. First, we immunoprecipitated HET/SAF-B from MCF-7 breast cancer cells lysed under low stringency (LS) and high stringency (HS) conditions (Fig. 2B). Under low-stringency conditions we observed coimmunoprecipitation of ER and HET/SAF-B, whereas under high-stringency conditions more HET/SAF-B was immunoprecipitated, but ER was dissociated from the complex. To demonstrate that the bands on the immunoblot are indeed antibody specific, we repeated the HET/SAF-B immunoprecipitation with HET/SAF-B antibodies preincubated with HET/SAF-B peptide, or without antibody.

As shown in Fig. 2C, only the immunoprecipitation with HET/SAF-B antibody resulted in a detectable band at the molecular mass of HET/SAF-B (~130 kDa), whereas no bands were detected using a peptide-preincubated antibody or no antibody. Thus, in breast cancer cells endogenous HET/SAF-B and ER interact, and this interaction can be detected when the cells are lysed under low-stringency conditions.

To investigate the ligand dependency of this interaction, we incubated MCF-7 cells in the absence of ligand and in the presence of  $\text{E}_2$  or Tam, and lysed them in LS buffer. After immunoprecipitation with HET/SAF-B antibodies, the membrane was immunoblotted with HET/SAF-B antibodies (Fig. 2D, left top panel) and ER antibodies (left bottom panel). While HET/SAF-B levels remained constant, coimmunoprecipitated ER levels changed. ER was detectable in the



**Fig. 2.** HET/SAF-B and ER Interact in Cells (Coimmunoprecipitations)

A, COS-7 cells were transiently transfected with expression constructs for HA-tagged ER (ER/HA) and HET/SAF-B as indicated, and lysed in low stringency buffer. The cell lysates were immunoprecipitated with an anti-HET/SAF-B antibody, subjected to electrophoresis, and immunoblotted with an anti-HA antibody (left panel). The cell lysates were immunoprecipitated with an anti-HA antibody, subjected to electrophoresis, and immunoblotted with an anti-HET/SAF-B antibody (right panel). B, MCF-7 cells were lysed in LS and HS buffer, the lysates from duplicate plates were immunoprecipitated with an anti-HET/SAF-B antibody, and the immunoprecipitates were subjected to electrophoresis. For the immunoblot anti-HET/SAF-B and anti-ER antibody were used. C, MCF-7 LS lysates were immunoprecipitated with an HET/SAF-B antibody, with HET/SAF-B antibodies preincubated with HET/SAF-B peptide, or without antibody. The immunoblots were performed with HET/SAF-B antibody (left top panel) and ER antibody (left bottom panel). The lysates were also immunoblotted with an ER antibody (right top panel). The bar graph represents intensity ratios of immunoprecipitated ER to immunoblotted ER in the lysates (see Materials and Methods). E, COS-7 cells were transfected with expression plasmids for HET/SAF-B and ER-HA. Treatment of the cells, immunoprecipitation, and immunoblotting were performed as described in panel C with the exception that HA antibody was used instead of ER antibody.

absence of ligand, low levels were detectable in the presence of  $E_2$ , but much higher levels of ER were coimmunoprecipitated in the presence of Tam. Since ER itself is known to be down-regulated by  $E_2$  via ubiquitin-mediated degradation (39, 40), as a control we also measured ER levels in the lysate (Fig. 2D, right top panel). In contrast to HET/SAF-B, which did not change with  $E_2$  and Tam treatment (data not shown), ER levels decreased dramatically after  $E_2$  treatment but were unaffected by Tam. To account for the differences in ER levels within the actual lysates, we measured the amount of ER in the immunoprecipitate and the lysate by densitometry and presented the

results as the ratio of ER levels immunoprecipitated with HET/SAF-B antibodies to ER levels in the lysate (Fig. 2D, bar graph). While the changes in ER levels complicate an exact quantitative analysis of the coimmunoprecipitation in the  $E_2$ -treated samples, Tam did not affect ER levels, and it can be clearly seen that ER binds more strongly to ER in the presence of Tam than in its absence (i.e. no ligand).

Finally, we confirmed that HET/SAF-B is strongly bound to ER in the presence of Tam by transfecting COS-7 cells with HET/SAF-B and an HA-tagged ER construct (Fig. 2E). As in MCF-7 cells, there was an association between HET/SAF-B and ER in the ab-



sence of ligand or in the presence of  $E_2$ , but again association was greater in the presence of Tam (*left bottom panel*). In cell lysates, HET/SAF-B levels did not change as a result of  $E_2$  or Tam treatment (data not shown). However, as seen with endogenous ER in MCF-7 cells, ER levels were reduced in COS-7 cells after  $E_2$  treatment (*right top panel*). When we corrected the changes in immunoprecipitated ER for the changes in endogenous ER levels, we were again able to detect a significant increase in the binding of HET/SAF-B to ER in the presence of Tam (Fig. 2E, *bar graph*). Thus, we conclude from our coimmunoprecipitation experiments that HET/SAF-B and ER interact, and that this interaction is stronger in the presence of the antiestrogen Tam.

### HET/SAF-B Overexpression Decreases ER Activity

As shown in Fig. 2, the association between HET/SAF-B and ER is stronger in the presence of Tam as compared with no ligand. This observation prompted us to study the effect of HET/SAF-B on the antagonist activity of Tam. To do this we performed transient transfection assays in ER-negative HepG2 cells using a single estrogen response element (ERE)-tk-luciferase construct as the reporter gene (Fig. 3A). The results in Fig. 3A represent the effect of HET/SAF-B on Tam acting as an antagonist of  $E_2$ -occupied ER; *i.e.* cells were incubated in the presence of both  $E_2$  and Tam. As expected, increasing concentrations of Tam resulted in a dose-dependent inhibition of  $E_2$ -mediated ER activity (pcDNAI curve). Cotransfection of 10 ng HET/SAF-B vector did not affect  $E_2$ -mediated activation of the ER in the absence of Tam, or when Tam was added at a low concentration that does not have an antagonistic effect ( $10^{-10}$  M). In contrast, at higher concentrations of Tam ( $10^{-9}$  to  $10^{-6}$  M) which antagonize  $E_2$  activation of ER, coexpression of HET/SAF-B (10 ng) significantly enhanced the antagonism by Tam.

We next addressed how increased overexpression of HET/SAF-B could affect the transcriptional activity of  $E_2$ -occupied ER. In the absence of ER, the addition of  $E_2$  did not result in a significant change in basal activity of the construct, and HET/SAF-B had no effect on this basal activity. As expected, transfection of ER led to an approximately 6-fold increase of transcriptional activity in the presence of  $E_2$ . The coexpression of increasing amounts of HET/SAF-B (0–150 ng) led to a significant dose-dependent decrease in ER activity (Fig. 3B). A similar HET/SAF-B-mediated repression was also seen in Saos-2 cells transfected with ER (data not shown). Increasing concentrations of HET/SAF-B (100 and 250 ng) were also able to further enhance the antagonist activity of Tam, as shown in Fig. 3C.

Using the same transfection system in HepG2 cells, but incubating the cells in the presence of Tam alone, Tam acts as an agonist and can activate the ER. We therefore tested whether HET/SAF-B overexpression


could affect Tam agonist activity. Figure 3D shows that Tam ( $10^{-8}$  M) caused a 2- to 2.5-fold increase in ER activity. Cotransfection with HET (100 ng) reduced this increase by 58%, while 250 ng HET completely abolished Tam agonist activity.

We next performed a series of additional control experiments (Fig. 4) to exclude a nonspecific repressor effect of HET/SAF-B. As shown in Fig. 3, A and B, basal activity of the ERE-tk-promoter was not inhibited by overexpression of HET/SAF-B. As expected, the deletion of the ERE sequence led to a tk-promoter construct that was also not affected by HET/SAF-B overexpression (Fig. 4A, *left bars*). In the same experiment the ERE-tk-promoter was inhibited by overexpression of HET/SAF-B (Fig. 4A, *right bars*), as shown previously (Fig. 3). As is common for transient transfection assays, the luciferase values were corrected for the values of a second cotransfected gene, which is, in our case, an SV40-promoter-driven  $\beta$ -galactosidase ( $\beta$ -gal) construct. Overexpression of HET/SAF-B did not change  $\beta$ -gal expression (Fig. 4B), thus representing another internal negative control. In several other experiments using other transcription factors and other reporter constructs, we again did not see a nonspecific repression by HET/SAF-B (detailed later).

### The ER-DBD Is Necessary for the Repressive Effects of HET/SAF-B

Most nuclear receptors including ER share a typical domain structure: a Zn finger DBD is flanked by an N-terminal region that displays a constitutive activator function domain 1 (AF-1) and the C terminus containing the ligand-binding domain, heterodimerization domain, and ligand-dependent activation function domain 2 (AF-2). To delineate the importance of the DBD of ER on HET/SAF-B-mediated repression, we made use of chimeric constructs in which the ER-DBD (aa 178–257) was replaced by a GAL4-DBD and tested reporter activity on four copies of a gal4-responsive element upstream of luciferase (gal4-luc). As a negative control we included the GAL4DBD alone (GAL4DBD). As a positive control we transfected wild-type ER, HET/SAF-B, and the ERE-tk-luc. All constructs were cotransfected with HET/SAF-B into HepG2 cells. The data are presented in Fig. 5A (*left panel*) as fold over control of each construct, since the activity of the different GAL4DBD constructs varied over magnitudes. The relative luciferase units for the controls (no estrogen and no HET/SAF-B) were ER = 1437.0, gal4DBD = 1.2, and ER-gal4DBD = 26.1.

As expected,  $E_2$  increased transcriptional activity from the ERE-tk-luc reporter construct, and the induction was repressed by coexpression of HET/SAF-B (Fig. 5A). Coexpression of the gal4DBD with the gal4-luc reporter construct resulted in basal activity that was not affected by  $E_2$  treatment and was also not affected by coexpression of HET/SAF-B. Expression of both the AF-1 and the AF-2 domains fused to




**Fig. 3. Overexpression of HET/SAF-B Inhibits ER Activity**

Cotransfection of the ERE-tk-luc (1  $\mu$ g) reporter gene with expression vectors coding for HET/SAF-B and ER as indicated in HepG2 cells. Values are the mean  $\pm$  SEM of triplicate wells, and the graphs are representative of at least three experiments each. A, Cells were transiently transfected with ER (25 ng) and 10 ng of pcDNAI or HET/SAF-B plasmids and incubated in the presence of  $10^{-9}$  M  $E_2$  and increasing amounts of Tam, as indicated (\*,  $P < 0.05$ ,  $t$  test). B, Cells were transfected with ER and HET/SAF-B plasmids as indicated. Open bars represent incubation in the absence of  $E_2$ , and black bars represent incubation in the presence of  $10^{-9}$  M  $E_2$ . C, Cells were transiently transfected with ER (25 ng) and HET/SAF-B (100 and 250 ng) plasmids and incubated in the presence of  $10^{-9}$  M  $E_2$  and increasing amounts of Tam, as indicated. D, Cells were incubated in the absence of ligand (open bar) and in the presence of  $10^{-8}$  M Tam (black bars), and transfected with ER (25 ng) and the indicated amounts of HET/SAF-B.

GAL4DBD (ER-GAL4DBD) behaved like wild-type ER with strong  $E_2$  inducibility. However, HET/SAF-B did not repress activity while it did repress wild-type ER activity. In addition, HET/SAF-B was not able to repress activity of either AF-1 fused to GAL4DBD, or AF-2 fused to GAL4DBD (data not shown). Interestingly, while HET/SAF-B was not able to repress activity of the ER-GAL4DBD chimera, HET/SAF-B was still able to bind to this chimera as shown by coimmunoprecipitation (Fig. 5A, right panel). The binding of HET/SAF-B to ER GAL4DBD substantiates the earlier *in vitro* GST binding experiments indicating that HET/SAF-B can bind ER not only in the DBD, but also in the Hinge/AF2 region. Thus, while HET/SAF-B can bind

ER-GAL4DBD, it cannot repress its activity, suggesting that the ERE-DBD is required for transcriptional repression.

To directly assess the importance of the ER-DBD in HET/SAF-B-mediated repression, we examined the effect of HET/SAF-B on the ER-DBD fused with a heterologous transcription factor (VP16). As a control we examined the effect of HET/SAF-B on VP-16 with a GAL4-DBD. As shown in Fig. 5B, the addition of increasing amounts of HET/SAF-B (50, 100, and 250 ng) did not affect the activity of VP16-GAL4 DBD on a GAL4 reporter construct. In contrast, HET/SAF-B caused a dose-dependent decrease of VP16-ER-DBD activity on a ERE-Luc reporter construct. Thus we can



**Fig. 4.** HET/SAF-B-Mediated Repression of ER's Transcriptional Activity Is Not the Result of a General Repression Mechanism. Cotransfection of ERE-tk-luc and tk-luc reporter genes with expression vectors coding for HET/SAF-B and ER as indicated. Bars are the mean  $\pm$  SEM of triplicate wells and each graph is representative of at least three experiments. A, HepG2 cells were transfected with expression plasmids for ER and HET/SAF-B, as indicated, and with the reporter constructs tk-luc and ERE-tk-luc, respectively. Cells were incubated in the presence of  $10^{-9}$  M  $E_2$ . B,  $\beta$ -Gal values measured from the experiment shown in panel A.

conclude that the ER-DBD can mediate the HET/SAF-B transcriptional repression effect.


A simple explanation for the repressive effect of HET/SAF-B would be if HET/SAF-B bound to the ERE-DBD and blocked ER binding to DNA. To examine this possibility, we asked whether HET/SAF-B had an effect on the DNA binding properties of ER. First we confirmed that HET/SAF-B could not bind directly to an ERE sequence using gel-shift assays and *in vitro* transcribed and translated HET/SAF-B (data not shown). To then examine whether HET/SAF-B could inhibit ER binding to DNA, we used a promoter interference assay originally described by Reese and Katzenellenbogen (41) in which an ERE is inserted between the cytomegalovirus (CMV) promoter (containing the TATA box) and the start site of transcription of the chloramphenicol acetyl transferase reporter gene (CMV-ERE-CAT) (Fig. 5C). Constitutive expression of this reporter construct was inhibited by coexpression of ER (Fig. 5C). This inhibition occurs in the absence of ligand, but is enhanced by addition of  $E_2$  or Tam, as previously shown by Reese and Katzenellenbogen. Coexpression of HET/SAF-B (10 ng) did not affect the activity of the reporter construct in the absence of ER and did not alter the ability of ER to inhibit reporter activity either in the absence or in presence of ligand. Overexpression of HET (250 ng) again did not affect the constitutive expression of the reporter construct in the absence of ER. However, this high concentration of HET/SAF-B actually increased the ability of ER to reduce reporter activity. This would suggest that binding of HET/SAF-B does not block the ability of ER to bind DNA, but rather that in the presence of high concentrations of HET/SAF-B more interference occurs.

## DISCUSSION

Nuclear receptors are divided into three groups: steroid receptors, retinoic acid/thyroid receptors, and orphan receptors. A fundamental difference between steroid receptors and retinoic acid/thyroid receptors is that the latter are DNA-bound active repressors in the absence of ligand. An active role for corepressors such as N-CoR (8, 12) and SMRT (14) for the silencing activity of unliganded retinoic acid/thyroid receptors has been well established. Recent findings of disturbed corepressor interaction with mutated thyroid receptors in patients with resistance to thyroid hormone support the importance of corepressors for the normal action of agonist- and antagonist-bound receptors (42–44).

In contrast to retinoid/thyroid receptors, steroid receptors show little DNA binding activity in the absence of ligand and thus are thought to have no silencing ability. However, recently it has become clear that steroid receptors are also found in repressor complexes, particularly when the receptor is bound to antagonists, and that the antagonist function may in part be mediated by corepressors (15, 45, 46).

In the presence of the antiestrogen Tam, ER can still dissociate from heat shock proteins and bind to DNA, but its AF-2 domain activity is inhibited (47). It has been shown that ER can bind the corepressors N-CoR and SMRT (45, 46). While binding of these corepressors is constitutive under *in vitro* conditions (48), coimmunoprecipitation experiments have indicated that N-CoR binds to ER only in the presence of Tam (46). The specific role of N-CoR and SMRT in the antagonist effect of Tam is unclear, but more detailed studies



**Fig. 5. ER-DBD Is Involved in HET/SAF-B's Mediated Repression of ER's Activity**

HepG2 cells were transiently transfected with expression vectors as indicated. Bars are the mean  $\pm$  SEM of triplicate wells and the graphs are representative of at least three experiments each. A, Cells were transiently transfected with various ER constructs (25 ng) and HET/SAF-B (200 ng), as indicated, and ERE-tk-luc and the Gal4-responsive promoter construct Gal4-luc, respectively. Since the activity of the different Gal4DBD constructs varied over magnitudes, the data are presented as fold over control calculated in relation to the activity of each construct seen in the absence of ligand. The right panel shows the result from an immunoprecipitation using lysates from COS-7 cells which were transiently transfected with expression plasmids for HET/SAF-B and ER-Gal4DBD. The cell lysates were immunoprecipitated with an anti-HET/SAF-B antibody, subjected to electrophoresis, and immunoblotted with an anti-ER antibody. B, Cells were transiently transfected with HET/SAF-B (as indicated), with 25 ng VP16-gal4DBD and VP16-ERDBD, and with the Gal4-responsive promoter construct Gal4-luc and ERE-tk-luc, respectively. C, Cells were transfected with 1  $\mu$ g CMV-ERE-CAT, and ER, and HET/SAF-B as indicated. Cells were incubated in the absence of ligand (white bars), in the presence of  $10^{-9}$  M  $E_2$  (gray bars), and  $10^{-7}$  M Tam (black bars).

have been performed concerning the agonist role of Tam. It has been shown that overexpression of N-CoR or SMRT can inhibit Tam's agonist activity (45, 46, 48). Additionally, reduction of N-CoR by microinjection of

N-CoR-specific antibodies can convert Tam into a full ER agonist displaying activity similar to estrogen (46). However, no data at present confirm that N-CoR or SMRT are actually responsible or necessary for the

antagonist activity of Tam. More recently a novel ER-specific corepressor, termed REA, has been discovered (15). REA can potentiate the antiestrogenic effect of Tam, but when overexpressed at high levels also inhibits estrogen activation of the ER.

In the present paper we describe another protein association with ER, that of the nuclear matrix protein HET/SAF-B, which also has properties consistent with its being an ER corepressor. Under *in vitro* conditions, HET/SAF-B interacts with ER in the absence of ligand, although the association is increased by Tam. Furthermore, coimmunoprecipitation experiments show that the interaction between HET/SAF-B and ER is stronger in the presence of Tam. The ability of Tam to recruit HET/SAF-B, as well as N-CoR and REA, to ER suggests an active corepression mechanism, although this remains to be specifically proven. Due to the ability of N-CoR and REA to alter the agonist/antagonist activity of Tam, it has been proposed that the ratio of corepressor to coactivator levels can alter the response of the ER to estrogen or Tam (46). Our studies with HET/SAF-B certainly fit this model. We show that HET/SAF-B potentiates Tam's antagonist activity, while overexpression of HET/SAF-B at high levels inhibits  $E_2$  and Tam agonist activities. Although HET/SAF-B's interaction with ER is weaker in the presence of  $E_2$  as compared with Tam, we were able to detect repression of  $E_2$ -activated ER, just as described for N-CoR (45) and REA (15). This repression probably represents inappropriate binding between ER and HET/SAF-B in the presence of  $E_2$  resulting from transient overexpression of HET/SAF-B. Under normal conditions we believe that Tam recruits HET/SAF-B to ER and that this association may be responsible, in part, for the antagonist effect of Tam.

Over the last couple of years it has become clear that transcriptional repression is an important strategy for fine regulation of growth, development, and differentiation. Despite the identification of corepressors, repressor motifs, and their targets, little is known about specific mechanisms of repression. Models that have been proposed include 1) interference with the formation or activity of the basal transcriptional machinery, 2) quenching of a transcriptional activator, and 3) induction of an inactive chromatin structure (reviewed in Ref. 49). It is likely that repression mediated by a corepressor like N-CoR is the result of a combination of these mechanisms. N-CoR is a large protein (270 kDa) that interacts with mSin3 and recruits histone deacetylase (21). Deacetylation results in conformational changes of the nucleosome structure, thereby limiting the accessibility of chromatin to the transcriptional machinery. In addition to its interaction with chromatin remodeling factors, Muscat *et al.* (50) have recently shown that N-CoR directly interacts with the basal transcription factors TFIIB, TAF<sub>II</sub>32, and TAF<sub>II</sub>70.

HET/SAF-B is a nuclear matrix protein with several recently described characteristics (31, 32, 35), which could be involved in repressive mechanisms. Like N-

CoR, which interacts with multiple factors, HET/SAF-B is probably part of a multiprotein complex regulating ER activity. While the work described here does not directly address the mechanism of HET/SAF-B-mediated repression, some potential mechanisms can be considered.

First, HET/SAF-B has recently been shown to bind to the C-terminal domain of RNA pol II (35) in yeast two-hybrid systems. As hypothesized for the interaction of N-CoR and basal transcription factors (50), it is conceivable that HET/SAF-B locks the transcriptional initiation complex into a nonfunctional state. Second, HET/SAF-B-mediated repression might also involve changes in histone acetylation, since in our own preliminary experiments treatment with the histone deacetylase inhibitor trichostatin A (51) relieves HET/SAF-B-mediated repression (S. Oesterreich, unpublished results). Third, it is possible that the RNA-binding domain of HET/SAF-B is involved in repression. In addition to HET/SAF-B, other RNA-binding proteins, such as L7/SPA (45), hnRNP U (30), and more recently RNA itself, SRA (52), have been described as coregulators of nuclear hormone receptor action.

While HET/SAF-B shares some of the characteristics of other coregulators, it is possible that its repressive action results from its ability to associate with the nuclear matrix. The presence of specific binding sites for ER, also called "acceptor proteins", in the nuclear matrix was postulated several years ago after *in vitro* reconstitution experiments showed binding of the ER to the nuclear matrix to be saturable and of high affinity (53, 54). We have shown previously that 1) HET/SAF-B is associated with the nuclear matrix in biochemical fractionations (31); 2) HET/SAF-B and ER can both be cross-linked to scaffold attachment regions (55); and 3) ER can associate with the nuclear matrix as shown by direct visualization with a green fluorescent protein-tagged ER (56). In this paper we have described HET/SAF-B as a nuclear matrix protein/scaffold attachment factor that associates with the ER.

Finally, it is important to define the domains of the steroid receptors that are involved in the interaction with the nuclear matrix. Eggert *et al.* (30) demonstrated that the C terminus of the glucocorticoid receptor was sufficient for hnRNP U-mediated repression. In contrast, Tang *et al.* (57, 58) and van Steensel *et al.* (59) have shown that the DBD of the glucocorticoid receptor is required for interaction with the nuclear matrix, and that replacement of the GR-DBD by a Gal4DBD resulted in loss of hnRNP U-mediated repression. In a similar way, HET/SAF-B-mediated repression is lost when the ER-DBD is substituted by a Gal4DBD. Indeed, the ER-DBD is sufficient for HET/SAF-B-mediated repression. However, the repression is not a result of inhibiting ER's ability to bind to DNA.

In summary, our study has revealed that the nuclear matrix protein/scaffold attachment factor HET/SAF-B directly binds to ER and inhibits its activity. The binding is stronger in the presence of Tam, as compared with no ligand, suggesting that HET/SAF-B-mediated

corepression may be involved in the antiestrogenic effects of Tam.

## MATERIAL AND METHODS

### Plasmid Constructs and Chemicals

The cloning of the HET/SAF-B expression construct (31) and of the mammalian expression vector for full-length ER has been previously described (60). To generate an HA-tagged full length ER construct, ER was PCR-amplified (61) using the following primers: sense 5'-GCGAATTCATGGCTTACCCCTACGACGTC-CCCGACTACGCCATGACCATGACCCTCCAC-3' comprising the HA-tag, and nucleotides 1-18 coding for the ER, and the antisense primer was 5'-GATGAATTCCTCAGACTGTGGC-AGGGAA-3' comprising nucleotides 1770-1789 of the ER. The PCR product was cloned into pcDNA3.1/V5/His-TOPO (Invitrogen, Carlsbad, CA). To generate a GST-fusion protein, the full-length HET/SAF-B clone (31) was cloned into *EcoRI* sites of the pGEX-2TK gene fusion vector (Pharmacia Biotech, Piscataway, NJ). Bacterial expression vectors for GST-ER fusion proteins containing the AF1, DBD/Hinge, DBD, Hinge, and AF2/Hinge domains were generated by performing ligation reactions with the appropriate PCR products and *EcoRI*/*Bam*HI-digested pGEX-2TK. The positions of the PCR primers (linked to *EcoRI* or *Bam*HI sites) within the ER $\alpha$  cDNA (61) are: AF1 -sense (1-20) and antisense (519-540); DBD/Hinge -sense (519-540) and antisense (849-869); DBD -sense (513-533) and antisense (730-746); Hinge -sense (750-771) and antisense (844-863); AF2/Hinge -sense (756-775) and antisense (1769-1788). The AF1/DBD construct was a kind gift of Dr. S. Kato (62, 63). The gal4-luc construct (pfluc) was purchased from Stratagene (La Jolla, CA). Constructs containing the activation domains (AF-1 and AF-2) of the ER fused to the gal4 DBD (amino acids 1-94) were a kind gift of Dr. O'Malley, and have been previously described (60). Briefly, the AF-1 domain of the ER was cloned upstream of the gal4DBD in pABgal94 (64) to create AF-1 gal4. The AF-2 domain of ER was cloned downstream of the gal4DBD to create AF2-gal4. Finally the AF-1 and AF-2 domains were cloned upstream and downstream, respectively, of the gal4DBD to create ER-gal4DBD. A construct containing a chimeric activator with the ER DBD and the activation region of VP16 was provided by Dr. P. Chambon and has been previously described (65). Finally, the ER-dependent promoter interference reporter plasmid was provided by Dr. B. Katzenellenbogen and has been described by Reese and Katzenellenbogen (41). The antiestrogen 4-hydroxytamoxifen (Tam) was a gift from Zeneca Pharmaceuticals (Macclesfield, UK). All other chemicals were purchased from Sigma (St. Louis, MO) unless stated otherwise.

### Cell Culture and Transient Transfection

Human breast cancer cells (MCF-7), human hepatocyte carcinoma cells (HepG2) cells, and human osteosarcoma cells (Saos-2) were maintained in improved MEM (IMEM) supplemented with 5% FBS (Life Technologies, Gaithersburg, MD), 200 U/ml penicillin, 200  $\mu$ g/ml streptomycin, 6 ng/ml insulin. COS-7 cells were maintained in DMEM + 10% FBS, 200 U/ml penicillin, 200  $\mu$ g/ml streptomycin, 6 ng/ml insulin. For reporter assays, cells were transiently transfected using Fugene (Roche Clinical Laboratories, Indianapolis, IN) following the manufacturer's protocol. One day before transfection cells were plated at  $8 \times 10^5$  in six-well plates. For E<sub>2</sub> induction experiments the cells were plated in serum-free medium which consisted of phenol red-free IMEM + 10 mM HEPES, pH 7.4 + 1  $\mu$ g/ml fibronectin (Life Technologies) + trace elements (Biofluids, Rockville, MD) + 1  $\mu$ g/ml transferrin (Life Technologies). Cotransfections were performed using 1  $\mu$ g reporter plasmid, 100 ng  $\beta$ -galactosidase ( $\beta$ -gal) expression

vector, and HET/SAF-B and ER plasmids as indicated in the figure legends for each experiment. Twenty-four hours after transfection, the medium was replaced with serum free medium containing the appropriate ligand. Forty-eight hours later cells were washed twice with PBS, and luciferase activity was measured using the Luciferase kit from Promega Corp. (Madison, WI).  $\beta$ -gal activity was measured as described (31), and the luciferase activities were normalized by dividing by the  $\beta$ -gal activity to give relative luciferase units. For determining CAT activity, we used a CAT enzyme-linked immunosorbent assay from Roche Clinical Laboratories and followed the manufacturer's instructions. Values were corrected for protein concentrations and are presented as relative CAT activity. For transient transfections, triplicate samples were measured in each experiment, and the data are presented as the average  $\pm$  SEM and are representative of at least three independent experiments. For coimmunoprecipitation experiments, COS-7 cells were plated at  $0.6 \times 10^6$  into 10-cm dishes, and transiently transfected with 5  $\mu$ g expression plasmids for HET/SAF-B and ER-HA. Twelve hours later the medium was replaced with phenol red-free IMEM + 5% charcoal-stripped serum and ligands as indicated in the figure legends. The cells were lysed 24 h later.

### In Vitro Protein-Protein Interaction (GST Pull-Down)

Overnight cultures of *Escherichia coli* BL21 expressing the appropriate fusion constructs were diluted 1:10 in LB medium and incubated for 1 h. GST only or GST-fusion proteins were induced for 2.5 h with 0.1 mM isopropyl- $\beta$ -D-thiogalactoside, followed by centrifugation, and resuspended at 1:100 in cell suspension buffer (1  $\times$  PBS, 100 mM EDTA, pH 8.0, 0.1 mM phenylmethylsulfonyl fluoride, 0.2  $\mu$ g/ml pepstatin, 0.2  $\mu$ g/ml leupeptin, 0.2  $\mu$ g/ml aprotinin, 0.2  $\mu$ g/ml antipain). Cells were sonicated and then centrifuged for 10 min at 4 C, and 400  $\mu$ g of crude *E. coli* bacterial extract proteins were incubated with 60  $\mu$ l glutathione Sepharose 4B beads (50% slurry, Pharmacia Biotech) (1 h, 4 C). For the binding assay, the beads were incubated in IPAB buffer (150 mM KCl, 0.1% Triton X-100, 0.1% NP40, 5 mM MgCl<sub>2</sub>, 20 mM HEPES, 20  $\mu$ g/ml BSA, protease inhibitors), and ligand was added as indicated in the experiments. *In vitro* transcription-translation mixture (TNT kit, Promega Corp.) containing <sup>35</sup>S-methionine was programmed with HET/SAF-B and ER expression plasmids. Lysates (10  $\mu$ l) were incubated with 60  $\mu$ l equivalent amounts of GST proteins (as assessed by Coomassie staining) at 4 C for 1 h. The beads were washed three times with IPAB buffer without BSA. Bound proteins were eluted in SDS sample buffer, resolved by SDS-PAGE, and visualized by fluorography.

### Generation of Anti-HET/SAF-B Monoclonal Antibodies

The peptide used for generation of a monoclonal antibody (mAb) to HET/SAF-B was identical to the peptide used to generate a polyclonal antibody described previously (31). The mAb was generated at the UTHSCSA Institutional Hybridoma Facility following methods described by Kohler (66) and Oi and Herzenberg (67). Briefly, spleen cells from two BALB/c female mice immunized subcutaneously three times with 50  $\mu$ g keyhole limpet hemocyanin-coupled peptide in Freund's adjuvant were fused with NS-1 myeloma cell line. A 50% PEG solution was added in a drop-wise manner. The subsequent dilution was performed in selection media (hypoxanthine, aminopterin, thymidine-containing medium), and 10 days later supernatants were screened for relevant antibody using the A156 HET/SAF-B peptide coupled to an alternative carrier (BSA). Culture supernatant from clone 6F7 was purified using the ImmunoPure (A/G) IgG purification kit (Pierce Chemical Co., Rockford, IL).



### Coimmunoprecipitation

MCF-7 cells were plated at  $2 \times 10^6$  cells in 10-cm dishes. The next day the media was changed to media containing 5% charcoal-stripped FCS and ligand as indicated in the figure legends. Twenty-four hours later the cells were lysed in low-stringency (LS) buffer (PBS, 0.1% NP40, protease inhibitors), and HS buffer (20 mM Tris, pH 7.4, 50 mM NaCl, 1 mM EDTA, 0.5% NP40, 0.5% SDS, 0.5% deoxycholate, and protease inhibitors), followed by sonication. Sodium tetrathionate (50  $\mu$ M) was added to the lysis buffer since it is known to selectively stabilize interactions between hormone receptors and the nuclear matrix (68); however, its addition is not essential for coimmunoprecipitation of ER and HET/SAF-B. The lysate was precleared with 50  $\mu$ l protein G-agarose for 30 min at 4 C, and then incubated overnight with 7  $\mu$ l HET/SAF-B mAb at 4 C. Protein G agarose was added for another 4 h, and the beads were pelleted and washed three times with the indicated buffer. For immunoprecipitation of HA-ER we precleared the lysates with 20  $\mu$ l protein A-agarose, incubated with 5  $\mu$ l HA antibodies (Babco, Richmond, CA) overnight, and finally added 20  $\mu$ l protein A-agarose. Bound proteins were eluted in SDS sample buffer, subjected to SDS-PAGE, and analyzed by immunoblotting (see below). For quantification, the scanned image was analyzed using NIH Image 2.0. The background intensity was subtracted from the intensity of the ER band in the immunoprecipitation, and this arbitrary number was divided by the intensity for the ER band in the immunoblot. The result is represented as an arbitrary number of the intensity ratio of immunoprecipitated ER to immunoblotted ER in the lysates.

### Immunoblotting

Proteins were resolved on 8% SDS-PAGE and electrophoretically transferred to nitrocellulose. The membrane was blocked in PBS/0.1% Tween 20 (PBST) + 5% milk for 1 h at room temperature. HET/SAF-B, ER (6F11, Novacastra, Newcastle upon Tyne, UK), and HA (Babco, Richmond, CA) antibodies were diluted at 1:1000, 1:100, and 1:1000, respectively, in PBST + 5% milk. After incubation for 1 h, the membrane was washed six times for 5 min each time with PBST, the membrane was incubated with horseradish peroxidase-linked anti-mouse IgG at 1:1000 (Amersham Pharmacia Biotech, Arlington Heights, IL) in PBST + 5% milk, washed six times for 5 min each time, and the signal was developed using enhanced chemiluminescence according to the manufacturers instructions (Pierce Chemical Co.).

### Acknowledgments

We would like to thank Drs. M. Gottardis, B.W. O'Malley, B. Katzenellenbogen, P. Chambon, and S. Kato for providing constructs [ERE-tk-luc (M.C.), ER-gal4 (B.O.M.), pCMV(ERE)<sub>2</sub>CAT (B.K.), GalVP16/pSG5 (P.C.), ER(C)-VP16 (P.C.), pGEX2T-AF1/DBD (S.K.)]. The authors are grateful to L. Hernandez for excellent technical assistance and to Dr. G. Chamness for critical reading of the manuscript. We also would like to thank Dr. C. Smith for providing access to laboratory facilities at Baylor College of Medicine.

Received May 28, 1999. Revision received November 19, 1999. Accepted December 9, 1999.

Address requests for reprints to: Steffi Oesterreich, Baylor College of Medicine, Breast Center, Alkek MS:600, One Baylor Plaza, Houston, Texas 77030. E-mail: steffio@bcm.tmc.edu.

This work was supported by an NIH Howard Temin Award (KO1 CA-77674) and a Department of Defense Grant

(DAMD17-98-1-8340) to S.O., a Breast Cancer Specialized Program of Research Excellence (PHS P50 CA-58183) and 5P01 CA30195 to C.K.O., a Susan G. Komen Breast Cancer Foundation Award to A.V.L., a NIH Cancer Center Support Grant (P30 CA-54174), and the Medical Research Council of Canada and Manitoba Health Research Council (J.R.D.). T.H. was supported by a Department of Defense Grant (DAMD 17-945-4112).

\*Present Address: Breast Center/Department of Medicine and Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030.

### REFERENCES

1. Tsai MJ, O'Malley BW 1994 Molecular mechanisms of action of steroid/thyroid receptor superfamily members. *Annu Rev Biochem* 63:451-486
2. Smith DF, Toft DO 1993 Steroid receptors and their associated proteins. *Mol Endocrinol* 7:4-11
3. Webb P, Lopez N, Uht RM, Kushner PJ 1995 Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. *Mol Endocrinol* 9:442-456
4. Rishi AK, Shao ZM, Baumann RG, Li XS, Sheikh MS, Kimura S, Bashilelahi N, Fonatna JA 1995 Estradiol regulation of the human retinoic acid receptor  $\alpha$  gene in human breast carcinoma cells is mediated via an imperfect half-palindromic estrogen response element and Sp1 motifs. *Cancer Res* 55:4999-5006
5. Porter W, Saville B, Hoivik D, Safe S 1997 Functional synergy between the transcription factor Sp1 and the estrogen receptor. *Mol Endocrinol* 11:1569-1580
6. Porter W, Wang F, Duan R, Safe S 1996 Role of estrogen receptor/Sp1 complexes in estrogen-induced heat shock protein 27 gene expression. *Mol Endocrinol* 10:1371-1378
7. Kato S, Kitamoto T, Masuhiro Y, Yanagisawa J 1998 Molecular mechanism of a cross-talk between estrogen and growth-factor signaling pathways. *Oncology* 55:5-10
8. Shibata H, Spencer TE, Onate SA, Jenster G, Tsai SY, Tsai MJ, O'Malley BW 1997 Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. *Recent Prog Horm Res* 52:141-164
9. Conneely OM, Kettelberger DM, Tsai M-J, O'Malley BW 1989 Promoter specific activating domains of the progesterone receptor. In: Roy AK, Clark JH (eds) *Gene Regulation by Steroid Hormones*. Springer Verlag, New York, pp 220-231
10. Bocquel MT, Kumar V, Stricker C, Chambon P, Gronemeyer H 1989 The contribution of the N- and C-terminal regions of steroid receptors to activation of transcription is both receptor and cell-specific. *Nucleic Acids Res* 17:2581-2595
11. Glass CK, Rose DW, Rosenfeld MG 1997 Nuclear receptor coactivators. *Curr Opin Cell Biol* 2:222-232
12. Hörlein AJ, Näär AM, Heinzl T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Söderström M, Glass CK, Rosenfeld MG 1995 Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. *Nature* 377:397-404
13. Sande S, Privalsky ML 1996 Identification of TRACs (T3 receptor-associating cofactors), a family of cofactors that associate with, and modulate the activity of, nuclear hormone receptors. *Mol Endocrinol* 10:813-825
14. Chen JD, Evans RM 1995 A transcriptional co-repressor that interacts with nuclear hormone receptors. *Nature* 375:454-457
15. Montano MM, Ekena K, Delage-Mourroux R, Chang W, Martini P, Katzenellenbogen BS 1999 An estrogen recep-

- tor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. *Proc Natl Acad Sci USA* 96:6947-6952
16. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y 1996 The transcriptional coactivators p300 and CBP are histone acetyltransferases. *Cell* 87:953-959
  17. Bannister AJ, Kouzarides T 1996 The CBP co-activator is a histone acetyltransferase. *Nature* 384:641-643
  18. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y 1996 A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. *Nature* 382:319-324
  19. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM 1997 Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. *Cell* 90:569-580
  20. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, Onate SA, Tsai SY, Tsai MJ, O'Malley BW 1997 Steroid receptor coactivator-1 is a histone acetyltransferase. *Nature* 389:194-198
  21. Heinzel T, Lavinsky R, Mullen T-M, Soderstrom M, Laherty C, Torchia J, Yang W-M, Brard G, Ngo S, Davie J, Seto E, Eisenman R, Rose D, Glass C, Rosenfeld M 1997 A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. *Nature* 387:43-48
  22. Nagy L, Kao H-Y, Chakravarti D, Lin R, Hassig C, Ayer D, Schreiber S, Evans R 1997 Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. *Cell* 69:373-380
  23. Bird RC, Stein GS, Lian JB, Stein JL 1997 Nuclear structure and gene expression. In: Buetow DE, Cameron IL, Padilla GM, Zimmerman AM (eds) *Cell Biology: A Series of Monographs*. Academic Press, New York, pp 35-295
  24. Getzenberg RH, Coffey DS 1990 Tissue specificity of the hormonal response in sex accessory tissues is associated with nuclear matrix protein patterns. *Mol Endocrinol* 4:1336-1342
  25. Barrack ER, Coffey DS 1980 The specific binding of estrogens and androgens to the nuclear matrix of sex hormone responsive tissues. *J Biol Chem* 255:7265-7275
  26. Barrack ER, Coffey DS 1982 Biological properties of the nuclear matrix: steroid hormone binding. *Recent Prog Horm Res* 38:133-195
  27. Rue M, Dunn R, Ruh T 1996 Interrelationships between nuclear structure and ligand-activated intracellular receptors. *Crit Rev Eukaryot Gene Expr* 62:271-283
  28. Getzenberg R, Pienta K, Coffey D 1990 The tissue matrix—cell dynamics and hormone action. *Endocr Rev* 11:399-417
  29. Barrett TJ, Spelsberg TC 1999 Nuclear matrix and steroid hormone action. *Vitam Horm* 55:127-163
  30. Eggert M, Michel J, Schneider S, Bornfleth H, Baniahmad A, Fackelmayer F, Schmidt S, Renkawitz R 1997 The glucocorticoid receptor is associated with the RNA-binding nuclear matrix protein hnRNP U. *J Biol Chem* 272:28471-28478
  31. Oesterreich S, Lee AV, Sullivan TM, Samuel SK, Davie JR, Fuqua SA 1997 Novel nuclear matrix protein HET binds to and influences activity of the HSP27 promoter in human breast cancer cells. *J Cell Biochem* 67:275-286
  32. Renz A, Fackelmayer FO 1996 Purification and molecular cloning of the scaffold attachment factor B (SAF-B), a novel human nuclear protein that specifically binds to S/MAR-DNA. *Nucleic Acids Res* 24:843-849
  33. Udvady A 1999 Dividing the empire: boundary chromatin elements delimit the territory of enhancers. *EMBO J* 18:1-8
  34. Bode J, Schlake T, Rios-Ramirez M, Mielke C, Stengert M, Kay V, Klehr-Wirth D 1995 Scaffold/matrix-attached regions: structural properties creating transcriptionally active loci. *Int Rev Cytol* 162A:389-454
  35. Nayler O, Stratling W, Bourquin J-P, Stagliar I, Lindemann L, Jasper H, Hartmann A, Fackelmayer F, Ullrich A, Stamm S 1998 SAF-B protein couples transcription and pre-mRNA splicing to SAR/MAR elements. *Nucleic Acids Res* 26:3542-3549
  36. Mortillaro MJ, Blencowe BJ, Wei X, Nakayasu H, Du L, Warren SL, Sharp PA, Berezney R 1996 A hyperphosphorylated form of the large subunit of RNA polymerase II is associated with splicing complexes and the nuclear matrix. *Proc Natl Acad Sci USA* 93:8253-8257
  37. Blencowe BJ, Nickerson JA, Issner R, Penman S, Sharp PA 1994 Association of nuclear matrix antigens with exon-containing splicing complexes. *J Cell Biol* 127:593-607
  38. Onate SA, Boonyaratanakornkit V, Spencer TE, Tsai SY, Tsai MJ, Edwards DP, O'Malley BW 1998 The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. *J Biol Chem* 273:12101-12108
  39. Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW 1999 Proteasome-dependent degradation of the human estrogen receptor. *Proc Natl Acad Sci USA* 96:1858-1862
  40. Alarid ET, Bakopoulos N, Solodin N 1999 Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. *Mol Endocrinol* 13:1522-1534
  41. Reese JC, Katzenellenbogen BS 1992 Examination of the DNA-binding ability of estrogen receptor in whole cells: implications for hormone-independent transactivation and the actions of antiestrogens. *Mol Cell Biol* 12:4531-4538
  42. Safer JD, Cohen RN, Hollenberg AN, Wondisford FE 1998 Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone. *J Biol Chem* 273:30175-30182
  43. Tagami T, Gu W-X, Peairs PT, West BL, Jameson JL 1998 A novel mutation in the thyroid hormone receptor defines a dual function domain that exchanges nuclear receptor corepressors and coactivators. *Mol Endocrinol* 12:1888-1902
  44. Liu Y, Takeshita A, Misti S, Chin BW, Yen PM 1998 Lack of coactivator interaction can be a mechanism for dominant negative activity by mutant thyroid hormone receptors. *Endocrinology* 139:4197-4204
  45. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB 1997 The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. *Mol Endocrinol* 11:693-705
  46. Lavinsky R, Jepsen K, Heinzel T, Torchia J, Mullen T-M, Schiff R, AD-R, Ricote M, Ngo S, Gemsch J, Hisenbeck S, Osborne C, Glass C, Rosenfeld M, Rose D 1998 Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. *Proc Natl Acad Sci USA* 95:2920-2925
  47. Jordan VC 1995 Studies on the estrogen receptor in breast cancer. *Breast Cancer Res Treat* 36:267-285
  48. Smith CL, Nawaz Z, O'Malley BW 1997 Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. *Mol Endocrinol* 11:657-666
  49. Hanna-Rose W, Hansen U 1996 Active repression mechanisms of eukaryotic transcription repressors. *Trends Genet* 12:229-234
  50. Muscat GEO, Burke LJ, Downes M 1998 The corepressor N-CoR and its variant RIP13a and RIP13D1 directly interact with the basal transcription factors TFIIB, TAF<sub>II</sub>32 and TAF<sub>II</sub>70. *Nucleic Acids Res* 26:2899-2907



51. Yoshida M, Horinouchi S, Beppu T 1995 Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. *Bioessays* 17:423-430
52. Lanz RB, McKenna NJ, Onate SA, Albrecht U, Wong J, Tsai SY, Tsai MJ, O'Malley BW 1999 A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. *Cell* 97:17-27
53. Belisle S, Bellabarba D, Lehoux J-G 1989 Estradiol receptor-nuclear interactions in aging mouse uteri: the role of DNA and nuclear matrix. *J Steroid Biochem Mol Biol* 32:41-43
54. Metzger D, Korach K 1990 Cell-free interaction of the estrogen receptor with mouse uterine nuclear matrix: evidence of saturability, specificity, and resistance to KCl extraction. *Endocrinology* 126:2190-2195
55. Samuel SK, Spencer VA, Bajno L, Sun JM, Holth LT, Oesterreich S, Davie JR 1998 In situ cross-linking by cisplatin of nuclear matrix-bound transcription factors to nuclear DNA of human breast cancer cells. *Cancer Res* 58:3004-3008
56. Htun H, Holth HL, Walker D, Davie JR, Hager GL 1999 Direct visualization of the human estrogen receptor  $\alpha$  reveals a role for ligand in the nuclear distribution of the receptor. *Mol Biol Cell* 10:471-486
57. Tang Y, DeFranco D 1996 ATP-dependent release of glucocorticoid receptors from the nuclear matrix. *Mol Cell Biol* 16:1989-2001
58. Tang Y, Getzenberg RH, Vietmeier BN, Stallcup MR, Eggert M, Renkawitz R, DeFranco DB 1998 The DNA-binding and tau2 transactivation domains of the rat glucocorticoid receptor constitute a nuclear matrix-targeting signal. *Mol Endocrinol* 12:1420-1431
59. van Steensel B, Jenster G, Damm K, Brinkmann AO, van Driel R 1995 Domains of the human androgen receptor and glucocorticoid receptor involved in binding to the nuclear matrix. *J Cell Biochem* 57:465-478
60. Castles CG, Oesterreich S, Hansen R, Fuqua SA 1997 Auto-regulation of the estrogen receptor promoter. *J Steroid Biochem Mol Biol* 62:155-163
61. Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J 1986 Sequence and expression of human estrogen receptor complementary DNA. *Science* 231:1150-1154
62. Kumar V, Green S, Stack G, Berry M, Jin J-R, Chambon P 1987 Functional domains of the human estrogen receptor. *Cell* 51:941-951
63. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. *Science* 270:1491-1494
64. Baniahmad A, Leng X, Burris TP, Tsai SY, Tsai MJ, O'Malley BW 1995 The tau 4 activation domain of the thyroid hormone receptor is required for release of a putative corepressor(s) necessary for transcriptional silencing. *Mol Cell Biol* 15:76-86
65. Tora L, White J, Brou C, Tasset D, Webster N, Scheer E, Chambon P 1989 The human estrogen receptor has two independent nonacidic transcriptional activation functions. *Cell* 59:477-487
66. Kohler G 1979 Fusion of lymphocytes. In: *Immunological Methods*. Academic Press, New York, vol 2
67. Oi VT, Herzenberg LA 1980 Immunoglobulin-producing hybrid cell lines. In: *Miscell B, Bas, SM (ed) Selected Methods in Cellular Immunology*. WH Freeman and Co, San Francisco, pp 351-372
68. Kaufmann S, Okret S, Wistrom A, Gustafsson J-A, Shaper J 1986 Binding of the glucocorticoid receptor to the rat liver nuclear matrix. *J Biol Chem* 261:11962-11967

# HET/SAF-B Overexpression Causes Growth Arrest and Multinuclearity and Is Associated with Aneuploidy in Human Breast Cancer<sup>1</sup>

Steven M. Townson, Toby Sullivan,  
QingPing Zhang, Gary M. Clark,  
C. Kent Osborne, Adrian V. Lee, and  
Steffi Oesterreich<sup>2</sup>

Breast Center, Departments of Medicine and Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030 [S. M. T., Q. P., G. M. C., C. K. O., A. V. L., S. O.], and Texas Tech University Health Science Center, Lubbock, Texas 79430 [T. S.]

## ABSTRACT

HET/SAF-B was originally cloned as a nuclear matrix protein that bound to matrix attachment regions and as a transcriptional repressor of the small heat shock protein hsp27. In addition, we have found recently that HET/SAF-B is also a corepressor of estrogen receptor activity. Estrogen receptor has a very well-described role in breast cancer, and aberrant expression of nuclear matrix and heat shock proteins has also been implicated in breast tumorigenesis. Therefore, we asked whether HET/SAF-B itself could be important in breast cancer. Toward this goal we examined its expression in breast cancer cell lines and asked whether HET/SAF-B can affect breast cancer cell proliferation. Finally, we studied HET/SAF-B expression in clinical breast cancer samples.

HET/SAF-B protein and mRNA were detected at varying levels in all of the eight breast cancer cell lines examined. Using a number of different approaches to modulate the level of HET/SAF-B protein in the cell, we found that HET/SAF-B levels are inversely correlated with cell proliferation. In addition, transfection of HET/SAF-B fused to the green fluorescent protein led to the formation of multinucleated cells not observed in cells transfected with green fluorescent protein alone, suggesting that this effect is a direct result of HET/SAF-B overexpression. Western blot analysis of HET/

SAF-B in 61 human breast tumors revealed widely varying levels of HET/SAF-B expression, with some tumors (16%) lacking any detectable HET/SAF-B. Statistical analysis showed that high HET/SAF-B expression in these tumors was associated with low S-phase fraction and with aneuploidy, consistent with our results from transfection experiments in tissue culture cells. We conclude that HET/SAF-B plays an important role in breast cancer, and we discuss possible mechanisms of the involvement of HET/SAF-B in cell proliferation and division.

## INTRODUCTION

HET/SAF-B was originally cloned as a protein binding to matrix/scaffold attachment regions (1) and as a NMP<sup>3</sup> binding to the hsp27 promoter in human breast cancer cells (2). Subsequently, it was shown to bind to the COOH-terminal domain of RNA polymerase II and to a subset of serine/arginine-rich RNA processing factors (SR proteins) and to function in mRNA splicing (3). This suggests that HET/SAF-B is involved in the formation of a "transcriptosomal" complex, bringing transcription and mRNA processing together. These macromolecular complexes have been shown previously to be associated with the nuclear matrix (4, 5).

The nuclear matrix consists of a protein-RNA network that is involved in structural organization of DNA within the nucleus, thereby controlling important regulatory processes such as transcription and DNA replication (reviewed in Ref. 6). Not surprisingly, many NMPs have been shown to be important in cell transformation. The NMP pattern of expression shows significant differences between normal and cancer tissue in bladder (7), colon (8), head and neck (9), prostate (10), and breast (11). Consistent with this, various NMPs were found to have potential as prognostic markers for cancer add (12, 13). Additionally, a role for the nuclear matrix in steroid hormone action was postulated many years ago (14-18) but only recently have specific NMPs been characterized that directly bind to hormone receptors and modulate their activity (19). For example, recently, the glucocorticoid receptor-interacting protein GRIP 120 has been identified as the NMP hnRNPU (20). We have shown recently that the NMP HET/SAF-B regulates the activity of the estrogen receptor (21).

HET/SAF-B binds to the ER and functions as an ER corepressor. In this way, HET/SAF-B is similar to several other

Received 3/15/00; revised 7/3/00; accepted 7/12/00.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> Supported by Breast Cancer Specialized Program of Research Excellence PHS P50 CA58183 (to C. K. O.), Howard Hughes Medical Institute Award Subgrant HHMI 76296-550801 (to S. O.), Howard Temin Award KO1 CA77674, United States Army Grant DAMD17-98-1-8340 (to S. O.), a Susan G. Komen Grant (to A. V. L.), and NIH Cancer Center Support Grant P30 CA54174.

<sup>2</sup> To whom requests for reprints should be addressed, at Department of Medicine, Breast Center, Baylor College of Medicine, One Baylor Plaza, MS:600, Houston, TX 77030. Phone: (713) 798-1623; Fax: (713) 798-1642; E-mail: steffio@bcm.tmc.edu.

<sup>3</sup> The abbreviations used are: NMP, nuclear matrix protein; hsp, heat shock protein; ER, estrogen receptor; GFP, green fluorescent protein; FBS, fetal bovine serum; SFM, serum-free medium; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; CMV, cytomegalovirus; RPA, RNase protection assay; FACS, fluorescence-activated cell sorter.

recently identified ER-interacting proteins, REA (repressor of estrogen receptor activity; Ref. 22), SMRT (the silencing mediator of retinoid and thyroid receptors; Refs. 23 and 24), and NcoR (nuclear receptor corepressor; Ref. 25), all of which also act as corepressors. Because estrogen is one of the most potent mitogens for breast cancer cells and is a known risk factor for breast cancer, a role of HET/SAF-B in estrogen action implies a role in ER-positive breast cancer cell growth control. Alternatively, it is also possible that HET/SAF-B can act as a transcriptional repressor independent of ER by interacting with other transcription factors. It has been shown that known steroid receptor-interacting proteins such as the coactivator SRC1 (26, 27), which was originally cloned as a steroid receptor cofactor, also mediates transactivation by other transcription factors including AP1 (28), serum response factor (28), nuclear factor- $\kappa$ B (29), cyclic AMP-responsive element binding protein, and signal transducers and activators of transcription (30). More recently SRC1 has also been found to bind to p53 and potentiate its transactivation, whereas two other ER coactivators, amplified in breast cancer (AIB1) and *Xenopus* steroid receptor coactivator (xSRC-3), were found to repress p53-mediated transactivation (31). This suggests that these factors might have important and distinct roles in tumorigenesis independent of their function as a steroid hormone receptor regulator.

HET/SAF-B is involved in a number of cellular processes that are associated with tumorigenesis. These include its role in the repression of hsp27, which has been shown to positively regulate breast cancer cell proliferation (32), as well as its role as a NMP and as an ER corepressor. Therefore, we have set out to analyze whether HET/SAF-B plays a role in breast cancer. Here we report that overexpression of HET/SAF-B causes growth inhibition and multinuclearity in cultured cells. Consistent with these findings from tissue culture, HET/SAF-B expression is associated with lower proliferation but also with aneuploidy in human breast tumor specimens. Thus, as predicted, HET/SAF-B plays a role in breast tumor behavior. Possible mechanism(s) will be discussed in more detail.

## MATERIALS AND METHODS

**Plasmid Constructs and Chemicals.** The cloning of the HET/SAF-B expression construct in pcDNA1 has been described previously (2). To generate an antisense construct, the full-length *EcoRI*-digested HET/SAF-B construct was cloned into pcDNA1 in the antisense direction, which was verified by sequencing. For the RNase protection assay, an *ApaI-EcoRV* HET/SAF-B fragment (99–443 bp) was cloned into pGEM5Zf(+) (Promega Corp., Madison, WI) and restriction-digested with *XhoI* (200 bp), and the probe was made using a T7 polymerase. The 36B4 probe has been described previously (33). A GFP-HET/SAF-B fusion protein with GFP positioned at the COOH-terminal of HET/SAF-B was cloned by ligating the full-length HET/SAF-B into the *EcoRI* site of pEGFP-C3 (Clontech, Palo Alto, CA). To generate an inducible HET/SAF-B construct, HET/SAF-B cDNA1 was subcloned from pcDNA1 using *EcoRI* and cloned into the unique *EcoRI* site in pUHD10–3 (34) to generate pUHDHET. The orientation was confirmed by sequencing. All chemicals were purchased from Sigma Chemical Co. (St. Louis, MO) unless stated otherwise.

**Cell Lines and Tumors.** Breast cancer cell lines MCF-7/MG, MDA-MB-468, MCF-7, MDA-MB-231, MCF-7/BK, MDA-MB-330, ZR-75, and T47D, along with CHO-K1 (Chinese hamster ovary) cells and T24 (human bladder carcinoma), were maintained in IMEM supplemented with 10% FBS, 2 mM glutamine, 50 IU/ml penicillin, and 50  $\mu$ g/ml streptomycin. NIH3T3 (mouse embryo) and 293 (transformed human embryonic kidney) cell lines were kept in DMEM (Life Technologies, Inc., Grand Island, NY), with the same supplements as IMEM. SFM consisted of IMEM + 10 mM HEPES (pH 7.4), 1  $\mu$ g/ml transferrin, 1  $\mu$ g/ml fibronectin, 2 mM glutamine, 50 IU/ml penicillin, 50  $\mu$ g/ml streptomycin, and trace elements (Biofluids, Rockville, MD). The clinical breast tumor specimens for the Western blot study were obtained from the National Tissue Resource maintained by our Breast Cancer Specialized Program of Research Excellence. These specimens were originally sent by hospitals throughout the United States to Nichols Institute Research Laboratories in San Juan Capistrano, CA, for routine measurements of steroid receptors and cell cycle analyses by flow cytometry. The flow cytometric assays were performed using methods described previously (35).

### Transfections, Cell Growth, and Cell Cycle Analysis.

All transfections were performed using Lipofectamine (Life Technologies, Inc.) or Fugene (Roche Molecular Biochemicals, Indianapolis, IN). Transient transfections were analyzed 48 h after transfection. To establish stable cell lines, NIH3T3 cells were cotransfected with pcDNA1 only or HET/SAF-B-pcDNA1 (2) and pSVneo, and transfected clones were selected in 1000  $\mu$ g/ml G418.

For growth analysis, cells were plated in quadruplicate at 2500 cells/well in a 96-well plate. The next day (day 0), cell number was assessed by MTT assay as described previously by us (36). Cells were then incubated in SFM or medium with 10% FBS, and cell number was determined at days 2, 4, and 6.

For colony formation assays, MCF-7/MG cells were transfected with 20  $\mu$ g of pcDNA1 vector control or HET/SAF-B-pcDNA1 sense and antisense, respectively, along with 1  $\mu$ g of pSVneo. After 3 weeks incubation in 400  $\mu$ g/ml G418, colonies were stained with 1% crystal violet.

293 cells, which display very high transfection efficiency, were used for proliferation assays measuring [ $^3$ H]thymidine incorporation into DNA. Cells ( $8 \times 10^4$ ) were plated in triplicate in six-well plates and transfected on day 2 with increasing amounts of pcDNA1 or HET/SAF-B-pcDNA1 antisense constructs. On day 4, the cells were incubated for 1 h with 1  $\mu$ M [ $^3$ H]thymidine (Amersham; 1 mCi/ml). After washing in cold PBS and cold 5% trichloroacetic acid, the cells were kept on ice for 30 min in the presence of 5% trichloroacetic acid and finally lysed in 0.5 M NaOH.

For generation of inducible HET/SAF-B-expressing cells, we used the tetracycline inducible expression system, which has been described in detail previously (34, 37). The tetracycline inducible MDA-MB-453rtTA cells were given to us by Dr. Douglas Yee (University of Minnesota). Briefly, cells were stably transfected with a plasmid (pUHD172–1-neo) expressing a protein termed rtTA (VP16 linked to a tetracycline binding protein). Stable clones were selected in 1000  $\mu$ g/ml G418, expanded, and then tested for expression of rtTA by transient transfection with a reporter plasmid (pUHD16–3) consisting of


seven tetracycline operator sequences upstream of a luciferase gene. Treatment of cells with doxycycline (an analogue of tetracycline) at 1  $\mu\text{g/ml}$  for 24 h indicated inducible luciferase expression (2–10-fold) in a number of clones. We used the clone with the highest inducibility (MDA-435rtTA1) for transfection with an expression plasmid containing HET/SAF-B under the control of a tetracycline-inducible CMV promoter (pUHDHET). After transfection, these cells were selected in 600  $\mu\text{g/ml}$  hygromycin and analyzed for inducible HET/SAF-B expression by Western blot analysis.

For the analysis of cell cycle distribution, cells were harvested, washed with PBS, fixed in 70% ethanol, and stored at  $-20^{\circ}\text{C}$ . Immediately before analysis on a FACS STAR PLUS (Becton Dickinson, San Jose, CA), propidium iodide and RNase were added to the cell pellet to final concentrations of 0.1 and 0.5  $\text{mg/ml}$ , respectively. Data were analyzed using CellQuest software.

The expression of HET/SAF-B throughout the cell cycle was investigated in T24 bladder carcinoma cells grown in IMEM containing 5% FBS by first growing the cells to confluence and then leaving them for 3 days to arrest in  $G_0$ - $G_1$  (37). The cells were then subcultured into 10-cm plates and plated at a density of  $1 \times 10^6$  per well. Cells lysates were produced at different time points after subculture by first washing the cells in PBS and then lysing them in high salt buffer [50 mM Tris-HCl (pH 7.8), 0.2 mM EDTA, 0.4 M NaCl, 10% glycerol, and 1%  $\text{NaPO}_4$ ] containing Protease Inhibitor Cocktail Tablets (Roche Molecular Biochemicals, Indianapolis, IN) used at the concentration suggested by the manufacturer. T24 cells were blocked in  $G_2$ -M using nocodazole. Cells were grown in 15-cm culture dishes and blocked by the addition of nocodazole at 40  $\text{ng/ml}$  for 18 h. Cell lysates were produced as described above. HET/SAF-B protein levels in the cell lysates were determined by Western blotting using 50  $\mu\text{g}$  of total protein and our monoclonal HET/SAF-B antibody (21).

**RNA and Protein Analysis.** The RPAs were performed as described previously (32) using a HET/SAF-B-specific probe as well as a probe for 36B4 as a loading control. For Western blot analysis, cell pellets were resuspended in 5% SDS or high salt buffer and sonicated, and 50  $\mu\text{g}$  of total protein were analyzed by Western blotting using HET/SAF-B antibody as well as a polyclonal antibody against the p85 subunit of PI3K (Upstate Biotechnology, Lake Placid, NY) as a loading control. For the quantitative Western blot analysis of human tumors, each gel contained 50  $\mu\text{g}$  of MCF-7 SDS extract as an internal standard. The HET/SAF-B bands were quantitated by densitometric scanning using NIH Image 1.6 software, and the levels were calculated in arbitrary units by the ratio of the integrated densitometry signal in the tumor sample relative to the internal standard on each gel. For the detection of GFP-HET/SAF-B fusion protein, an anti-GFP antibody was used at a 1:1000 dilution (Clontech, Palo Alto, CA).

**Statistical Analysis.** All statistical analyses were performed using SAS (Version 6.11; SAS Institute, Cary, NC) running on a Sun Microsystems SparcServer 1000. Relationships between HET/SAF-B expression and S-phase fraction and between HET/SAF-B and ER expression were analyzed using Spearman's rank correlation coefficients. The relationship be-



**Fig. 1** HET/SAF-B expression in breast cancer cell lines. For the Western blot (A), 50  $\mu\text{g}$  of SDS-protein extracts were loaded onto 6% SDS-PAGE, transferred to nitrocellulose, and blotted with HET/SAF-B- and p85-specific antibodies. For the RPAs (B), 20  $\mu\text{g}$  of RNA from the cell lines used in the Western blot were used, and the protected HET/SAF-B fragment of 240 bp is shown. 36B4 was used as a loading control.


tween HET/SAF-B expression and ploidy was analyzed using a  $t$  test.

## RESULTS

### Expression of HET/SAF-B in Breast Cancer Cell Lines.

Renz and Fackelmayer (1) have shown previously that *HET/SAF-B* is a ubiquitously expressed gene. Northern blot analysis using a variety of different human cancer cell lines and different tissues detected HET/SAF-B mRNA in all analyzed samples. To see how it is expressed in various breast cancer cell lines, we performed Western blot analysis using the HET/SAF-B antibody and a p85 antibody as a loading control (Fig. 1). HET/SAF-B protein levels varied between cell lines, with the highest expression in MDA-MB-231, ranging to almost undetectable levels in ZR-75 cells. The subsequent RPA (Fig. 1B) indicated that ZR-75 cells do express HET/SAF-B mRNA. Thus, although *HET/SAF-B* is a ubiquitously expressed gene, the levels in breast cancer cell lines vary.

**Overexpression of HET/SAF-B in Tissue Culture Cell Lines and Effect on Cell Growth.** To establish the relationship between HET/SAF-B expression and cell proliferation, we attempted to transfect HET/SAF-B into cell lines. A number of initial efforts to isolate stable breast cancer cell lines that constitutively overexpressed HET/SAF-B were unsuccessful; after transfection with HET/SAF-B-pcDNA1, some drug-resistant clones formed, but none survived further passaging in culture. In contrast, we were able to select several hundred control clones transfected with pcDNA1 alone. These results indicate that HET/SAF-B either inhibits proliferation or is toxic to the cells. To circumvent this problem, we used a tetracycline-inducible



**Fig. 2** Inducible expression of HET/SAF-B and growth inhibition in MDA-MB-435rtTA cells. **A**, MDA-MB-435rtTA cells containing a HET/SAF-B plasmid under control of a tet-inducible CMV promoter were induced with doxycycline for 24 h, lysed in 5% SDS, and analyzed by Western blotting using HET/SAF-B-specific antibodies. **B**, cells were plated in 96-well plates in quadruplicate in 10% serum (■) and in SFM (□), and doxycycline was added the next day. On day 5, MTT assay was performed, and the data are presented as percentage growth inhibition as compared with control cells; bars, SD.

system in MDA-MB-435 cells (MDA-435 rtTA1). These cells were transfected previously with an inducible transactivator (etoposide linked to a tetracycline binding protein) and show 5–10-fold induction of reporter gene activity in the presence of the inducer doxycycline. We therefore cloned the HET/SAF-B cDNA downstream of a tetracycline-regulated CMV promoter and generated inducible HET/SAF-B clones. We were able to isolate two inducible clones, which showed increased HET/SAF-B expression when cells were stimulated with doxycycline for 24 h (Fig. 2A). We performed MTT growth assays to measure proliferation rate in these clones as compared with control clones and detected a significant decrease in cell number when cells were stimulated with doxycycline (Fig. 2B). The HET/SAF-B overexpressing cells showed growth inhibition in 10% serum as well as in serum-free medium. However, further passaging of those cells resulted in loss of inducibility of HET/SAF-B expression. Because we detected a slight leakiness of the system in transient assays, *i.e.*, expression of HET/SAF-B in the absence of inducer (data not shown), we suggest that the clones were lost because of a low overexpression of HET/SAF-B, even in the absence of doxycycline.

Because NIH3T3 cells are known to be less sensitive to overexpression of exogenous genes as compared with breast cancer cells, we attempted to generate stable HET/SAF-B transfectant overexpression clones with these cells. We could not detect any HET/SAF-B by Western blot in parental NIH3T3 cells, which could be attributable either to very low expression

or to the inability of the antibody raised against human HET/SAF-B to recognize murine HET/SAF-B. Just as in breast cancer cells, drug-resistant colonies formed after transfection in NIH3T3 cells, but most did not survive passaging, although we were able to select a high number of control clones transfected with the empty vector pcDNA1. Finally, we were able to generate one HET/SAF-B overexpressing clone (#25), as confirmed by Western blotting (Fig. 3A). Anchorage-dependent growth assays (MTT assay) showed that the HET/SAF-B-overexpressing clone grew much slower than two vector-alone control clones, either in SFM or in 10% FBS (Fig. 3B). Furthermore, cell cycle analysis confirmed that the slower growth of the HET/SAF-B-overexpressing clone was accompanied by a decrease in S-phase (15.6–4.0%). Thus, HET/SAF-B overexpression results in growth inhibition. This growth inhibition seems to be independent of ER, because it can be observed in ER-negative cells.

**Overexpression of a GFP-HET/SAF-B Fusion Protein in Tissue Culture Cell Lines.** As a final approach to generate HET/SAF-B-overexpressing clones, we used a GFP-HET/SAF-B fusion protein for our transfection studies. We hypothesized that using the fluorescently tagged HET/SAF-B would improve our screening procedure, because only fluorescent clones would be picked, expanded, and analyzed for overexpression. GFP-HET/SAF-B is functional, because it was able to corepress ER activity (data not shown), similar to our findings using the HET/SAF-B construct (21).

We transfected MDA-MB-435 cells using the GFP-HET/SAF-B construct and GFP only as a control. Of 20 fluorescent clones that were transfected with GFP alone, all 20 were still brightly fluorescent after keeping them in culture for 4–6 weeks (data not shown). However, of 120 fluorescent GFP-HET/SAF-B clones that we originally isolated, only 4 were still fluorescent after expanding them (2–3 weeks). In two of those clones, HET/SAF-B localized to the cytoplasm (data not shown), which has not been described before and which might represent an “escape mechanism” from the growth-inhibitory and/or toxic effects of HET/SAF-B overexpression. The other two clones showed only very faint fluorescence, in only approximately 1–3% of the cells, and HET/SAF-B was not detectable by Western blotting using the HET/SAF-B antibody, presumably because of the low level of expression in a small number of cells. However, a very weak signal could be detected using an anti-GFP antibody on Western blots (data not shown). We did not perform any growth assays with these clones because the expression of the exogenous HET/SAF-B was considerably lower than endogenously expressed HET/SAF-B, so that significant effects were unlikely to be observed. Thus, although the use of a GFP-HET/SAF-B fusion protein allowed us to perform a more efficient primary screen of the colonies, subsequently we were again unable to keep HET/SAF-B-overexpressing cells in culture.

We did, however, notice an obvious morphological change in the GFP-HET/SAF-B-expressing MDA-MB-435 cells as compared with the GFP-expressing cells (Fig. 4A). Many GFP-HET/SAF-B cells were polynucleated, with some cells having as many as 20 nuclei. We did not detect any polynucleated cells in the control GFP-transfected cells. We confirmed this result in transiently transfected CHO-K1 cells (data not shown), where




Fig. 3 Overexpression of HET/SAF-B and growth inhibition in NIH3T3 cells. *A*, for the Western blot, 50  $\mu$ g of SDS-protein extracts were loaded onto 6% SDS-PAGE, transferred to nitrocellulose, and blotted with HET/SAF-B-specific antibodies. *B*, cells were plated in quadruplicate in 96-well plates in 10% serum or SFM, and MTT assays were performed on the next day (day 0) and on day 2, 4, and 6. Bars, SD.





Fig. 4 Generation of multinucleated cells after GFP-HET/SAF-B transfection. *A*, MDA-MB-435 cells were transfected with GFP only or with GFP-HET/SAF-B. Cells were observed using a FITC filter on an Olympus CK40 fluorescence microscope. Representative pictures of one control clone (GFP) and two GFP-HET/SAF-B clones are shown. *B*, 293 cells were transiently transfected with GFP or GFP-HET/SAF-B, and representative pictures were taken. *C*, transfected 293 cells were sorted on a FACS, and DNA histogram analysis was performed on fluorescent cells only.

again we detected many polynucleated cells in the GFP-HET/SAF-B-overexpressing cells but not in the GFP cells. Finally, we repeated the transient transfection in 293 cells, which display very high transfection efficiency. As seen in MDA-MB-435 and CHO-K1 cells, we again observed many polynucleated cells among the HET/SAF-B-overexpressing cells. Depending on the cell line used, we detected multinucleated cells in 1–5% of the cells. We analyzed the cell cycle distribution of the transfected 293 cells by sorting the fluorescent cells and subjecting them to DNA histogram analysis (Fig. 4D). As shown previously (in the NIH3T3 transfection in Fig. 3), the number of cells in S-phase was decreased, from 34% in control cells to 12% in GFP-HET/

SAF-B-overexpressing cells. We also observed a block in G<sub>2</sub>-M in the HET/SAF-B-overexpressing cells (23–44%). Thus, overexpression of GFP-HET/SAF-B was associated with multinuclearity and significant changes in cell cycle.


Because overexpression of HET/SAF-B seemed to block cells in G<sub>2</sub>-M, we asked whether HET/SAF-B protein levels vary through the cell cycle. To answer this question, we used T24 human bladder carcinoma cells that can be easily synchronized by contact inhibition as described previously (38). They reenter the cell cycle upon replating at a lower dilution. Breast cancer cells do not synchronize upon confluence but can be synchronized by withdrawal of serum. However, reentry into the





cell cycle by serum stimulation may produce artifactual results because serum stimulation may affect HET/SAF-B levels or phosphorylation. Thus, we used synchronized T24 cells. In addition, we analyzed T24 cells that were blocked in G<sub>2</sub>-M by treatment with nocodazole. Cell cycle analysis was performed by FACS, and as expected, we were able to obtain cells synchronized in G<sub>0</sub>-G<sub>1</sub>, G<sub>1</sub>-S, and G<sub>2</sub>-M (Fig. 5A). Subsequent Western blot analysis demonstrated that HET/SAF-B was expressed throughout the cell cycle, but the levels of HET/SAF-B protein increased during S-phase and peaked in G<sub>2</sub>-M (Fig. 5B). The expression of HET/SAF-B in nocodazole-treated cells confirmed the increase of HET/SAF-B expression in G<sub>2</sub>-M. Thus, HET/SAF-B protein levels are at their highest in G<sub>2</sub>-M, which is the stage at which overexpressed HET/SAF-B blocks cells.

**Transient Modulation of HET/SAF-B Levels in Tissue Culture Cell Lines.** As shown in the above experiments, it was difficult to stably integrate HET/SAF-B into the genome of various cell lines. Thus, as a final approach to prove the effect of HET/SAF-B on proliferation, we used a transient tissue culture assay in breast cancer cells commonly used by other investigators (39) to demonstrate negative effects of genes on growth. In this assay, cells are transfected with the gene of interest and a selection marker and then grown in selection media until colonies can be stained and counted. We transfected MCF-7/MG cells with pSV-neo plasmid and empty vector only (pcDNA1) or HET/SAF-B cDNA in sense or antisense orientation. Transfection of the antisense construct resulted in decreased HET/SAF-B expression at both RNA and protein levels (data not shown). The cells were selected for resistance to G418, and after 3 weeks, colonies were stained with crystal violet (Fig. 6A). The number of colonies was dramatically reduced after transfection of HET/SAF-B sense cDNA, whereas antisense transfection had no significant effect compared with pcDNA1



**Fig. 6** Transient modulation of HET/SAF-B levels in MCF-7 cells. Colony formation assay in MCF-7 breast cancer cells is shown. MCF-7/MG cells were transfected with pcDNA1 vector control or with pcDNA1-HET/SAF-B in antisense or sense orientation, along with pSVneo, and incubated in G418 for 3 weeks. After staining with crystal violet, pictures were taken.

only. The inhibition of colony growth after HET/SAF-B overexpression confirms its growth inhibition. We were, however, surprised by the finding that antisense transfection did not increase colony formation in this experiment, and this could have several reasons. For instance, it is possible that we did not decrease the endogenous levels enough for generation of a phenotype in the transfected MCF-7 cells. Therefore, we repeated the transfection of the antisense DNA in 293 cells, which are known to display very high transfection efficiency. Determining [<sup>3</sup>H]thymidine incorporation into DNA as a direct measurement of cell proliferation, we were able to detect a dose-




Fig. 7 Expression of HET/SAF-B in clinical breast cancer samples. A Western blot using 50  $\mu$ g of SDS extracts from breast tumors and HET/SAF-B-specific antibodies is shown. In the left lane, an SDS-extract from MCF-7 breast cancer cells was loaded as a positive control. Arrow, position of HET/SAF-B.

dependent increase in the proliferative index after transfection of the antisense construct (data not shown), thus again supporting our other data describing HET/SAF-B as a negative growth regulator.

**Expression of HET/SAF-B in Clinical Breast Cancer Specimens.** Lastly, we asked whether in tumor samples we could detect an association of HET/SAF-B with proliferative markers in a way reflective of our findings from tissue culture experiments. Therefore, we analyzed HET/SAF-B expression in human breast cancer specimens and correlated this with proliferation rate as measured by S-phase fraction. We measured HET/SAF-B levels in 61 primary breast tumors by Western blot (a representative blot is shown in Fig. 7) and found that, as in the cell lines, HET/SAF-B protein content varied widely. Some tumors expressed high amounts (e.g., no. 5), some moderate (e.g., no. 6), and in 10 tumors (16%), no HET/SAF-B could be detected (e.g., no. 8), even after prolonged exposure of the film. The same extracts were analyzed for histone H3 levels,<sup>4</sup> and samples that were HET/SAF-B negative still showed abundant histone H3 expression. Thus, we can exclude artifacts such as nonspecific protein degradation. We quantified HET/SAF-B protein levels by densitometry, and statistical analysis revealed a trend toward a negative correlation with S-phase fraction. The correlation was only borderline significant (Spearman's rank correlation,  $-0.22$ ;  $P = 0.08$ ), but the sample size was relatively small, and a larger analysis is planned to verify this correlation. We also detected an association between HET/SAF-B and ploidy; high HET/SAF-B levels were associated with increased aneuploidy ( $P = 0.021$ ). HET/SAF-B levels did not correlate with ER levels (Spearman's rank correlation,  $-0.064$ ;  $P = 0.62$ ), although as shown in a number of previous studies, we were able to detect a correlation between high ER levels and low S-phase (Spearman's rank correlation,  $-0.23$ ;  $P = 0.025$ ). Thus, in human breast tumors, HET/SAF-B protein expression varied widely, and higher levels were associated with aneuploidy. Also, we detected a trend toward a negative association

with proliferation, which is consistent with our findings from tissue culture experiments.

## DISCUSSION

HET/SAF-B is a NMP that was cloned in our laboratory as a negative regulator of hsp27 expression (2) and in the laboratory of Renz and Fackelmayer (1) as a scaffold/matrix attachment site binding protein. The nuclear matrix was postulated many years ago to interact with nuclear hormone receptors (14–18), but only recently have specific NMPs been identified that bind directly to hormone receptors and modulate their activity (19). Because ER, like HET/SAF-B, is also involved in regulating hsp27 expression (40), we asked whether HET/SAF-B interacts with this receptor and modulates its activity and found that HET/SAF-B acts as an ER corepressor. Here we show more generally that HET/SAF-B is a growth inhibitor independent of its interaction with ER, blocking the cell in  $G_2$ -M, and in some situations causing multinuclearity.

We provide several lines of evidence that HET/SAF-B affects proliferation: (a) breast cancer cells with inducible HET/SAF-B expression grew significantly slower than their appropriate control clones; (b) NIH3T3 cells overexpressing HET/SAF-B also showed a significant decrease in growth; and (c) transient overexpression and underexpression of HET/SAF-B results in decreased colony formation and increased cell proliferation, respectively. Although interpretation of results from a single overexpressing NIH3T3 clone is limited because of the possible unpredictable effect of integration, the parallel evidence from HET/SAF-B-inducible MDA-MB-435rtTA cells and additional results from transient transfection assays in MCF-7 and 293 cells allow us to conclude that HET/SAF-B overexpression results in growth inhibition. In addition, in cultured cells as well as in clinical breast tumors, HET/SAF-B protein levels were inversely correlated with S-phase fraction, which is a direct measure of proliferation rate. In the present relatively small sample of breast tumors ( $n = 61$ ), this correlation did not quite reach statistical significance ( $P = 0.08$ ), and we are currently designing a larger study to address how well HET/SAF-B correlates with S-phase and other prognostic factors and whether HET/SAF-B levels could predict clinical outcomes of breast cancer patients. We have also shown that down-regulation of endogenous HET/SAF-B can lead to a higher growth rate, consistent with HET/SAF-B being a negative growth regulator, the absence of which may lead to excessive growth in tumors. Indeed, we have found that some breast tumors did not express HET/SAF-B protein at a detectable level.

The growth-inhibitory effects of overexpressed HET/SAF-B in ER positive cells can be readily explained by HET/SAF-B being an ER corepressor. It is feasible that HET/SAF-B suppresses estrogen-dependent transcriptional pathways related to breast epithelial cell proliferation, thus resulting in growth arrest. It is of interest to mention that the breast cancer susceptibility gene *BRCA1* was shown recently to inhibit ER activity in transient transfection assays (41).

The exact mechanism of estrogen-induced proliferation is yet to be defined, but we think that HET/SAF-B could play a role. When cells are primed to respond to estrogen in  $G_0$ - $G_1$  and in  $G_1$ -S-phase transition (42), HET/SAF-B levels are at their

<sup>4</sup> C. K. Osborne, unpublished results.



lowest. In contrast, when cells do not respond to estrogen (in M phase), HET/SAF-B levels are high. Overexpression of HET/SAF-B, for instance as a result of our transfection studies, results in high HET/SAF-B levels at all parts of the cell cycle, including the phases when cells are primed to respond to estrogen. This presumably leads to inappropriate ER corepression, thus resulting in growth arrest.

As described by us (21) and others (1, 3), HET/SAF-B clearly has other functions, independent of its ER corepressor activity. These characteristics or other functions of HET/SAF-B yet to be defined might explain the growth-inhibitory effect of HET/SAF-B in ER-negative cells. For instance, hsp27 has clearly been shown to be associated with increased breast cancer cell growth, so that its down-regulation by HET/SAF-B could result in growth inhibition. It is also likely, just as discovered for other steroid receptor cofactors (42), that HET/SAF-B does not interact exclusively with ER. Indeed, our preliminary data<sup>5</sup> indicate that HET/SAF-B can also inhibit the activity of other members of the steroid receptor as well as the retinoic acid/thyroid receptor families. Again, this regulation of other proteins besides the ER could explain the observed ER-independent effects.

HET/SAF-B has also been shown to bind to the COOH-terminal domain of RNA polymerase II and to a subset of serine/arginine-rich RNA processing factors (SR proteins; Ref. 3). This suggests that HET/SAF-B is involved in the formation of a transcriptosomal complex, bringing transcription and pre-mRNA processing together. The role of HET/SAF-B in this complex might be to prevent processing of mRNA transcripts, which would be consistent with the function of HET/SAF-B as a transcriptional repressor. Such an activity has been shown for CstF-50, which also binds to RNA polymerase II and is thought to prevent the processing of mRNA transcripts containing error (43). Overexpression of HET/SAF-B may disrupt the balance in the interaction with these splicing proteins, leading to a decrease in RNA processing and possibly resulting in growth arrest.

Finally, the attachment of HET/SAF-B to the nuclear matrix should be mentioned. The nuclear matrix organizes DNA into loop domains, the bases of which contain the S/MAR DNA sequences. It is the scaffold attachment factors such as HET/SAF-B that bind these sequences, thus connecting the chromatin to the NMP structures. The high levels of HET/SAF-B seen in G<sub>2</sub>-M may also reflect its role in the packaging of chromatin for mitosis. When cells are in G<sub>2</sub>-M, most transcription is repressed, and there is a dramatic increase in HET/SAF-B protein levels, which suggests that HET/SAF-B could be a major factor in the general repression of transcription at this phase of the cell cycle. The effect on cell proliferation when HET/SAF-B is overexpressed in both ER-positive and ER-negative cell lines may be the result of high intracellular HET/SAF-B levels throughout the cell cycle, leading to disruption of the organization of the transcriptionally active chromatin normally seen in G<sub>0</sub>-G<sub>1</sub> and S-phase, thus producing transcriptionally inactive chromatin as seen in G<sub>2</sub>-M. This repression then leaves cells without the

appropriate protein machinery to continue through the cell cycle and they become blocked.

In addition to the growth-inhibitory effects of overexpressed HET/SAF-B, our experiments with GFP-HET/SAF-B show that overexpression causes cells to be multinucleated. Furthermore, in breast tumors, HET/SAF-B was strongly associated with aneuploidy. Multinuclearity and aneuploidy are two of the most common features of tumor cells, but the exact molecular basis for these phenotypes is unknown (44, 45). Because HET/SAF-B overexpression results in a block in G<sub>2</sub>-M, one could imagine that overexpressed HET/SAF-B somehow disrupts mitosis, either directly by altering the condensation of chromatin or indirectly by repressing genes involved in spindle formation and cytokinesis.

In summary, we have provided evidence that the NMP HET/SAF-B plays several roles in human breast cancer. Our current studies are aimed at further identifying the mechanism(s) of HET/SAF-B-mediated growth inhibition and multinuclearity.

## REFERENCES

1. Renz, A., and Fackelmayer, F. O. Purification and molecular cloning of the scaffold attachment factor B (SAF-B), a novel human nuclear protein that specifically binds to S/MAR-DNA. *Nucleic Acids Res.*, 24: 843-849, 1996.
2. Oesterreich, S., Lee, A. V., Sullivan, T. M., Samuel, S. K., Davie, J. R., and Fuqua, S. A. Novel nuclear matrix protein HET binds to and influences activity of the HSP27 promoter in human breast cancer cells. *J. Cell. Biochem.*, 67: 275-286, 1997.
3. Nayler, O., Stratling, W., Bourquin, J. P., Stagljar, I., Lindemann, L., Jasper, H., Hartmann, A. M., Fackelmayer, F. O., Ullrich, A., and Stamm, S. SAF-B protein couples transcription and pre-mRNA splicing to SAR/MAR elements. *Nucleic Acids Res.*, 26: 3542-3549, 1998.
4. Mortillaro, M. J., Blencowe, B. J., Wei, X., Nakayasu, H., Du, L., Warren, S. L., Sharp, P. A., and Berezney, R. A hyperphosphorylated form of the large subunit of RNA polymerase II is associated with splicing complexes and the nuclear matrix. *Proc. Natl. Acad. Sci. USA*, 93: 8253-8257, 1996.
5. Blencowe, B. J., Nickerson, J. A., Issner, R., Penman, S., and Sharp, P. A. Association of nuclear matrix antigens with exon-containing splicing complexes. *J. Cell Biol.*, 127: 593-607, 1994.
6. Bird, R. C., Stein, G. S., Lian, J. B., and Stein, J. L. Nuclear structure and gene expression. In: D. E. Buetow, I. L. Cameron, G. M. Padilla, and A. M. Zimmerman (eds.), *Cell Biology: A Series of Monographs*. New York: Academic Press, 1997.
7. Getzenberg, R. H., Konety, B. R., Oeler, A., Quigley, M. M., Hakam, A., Becich, M. J., and Bahnson, R. B. Bladder cancer associated nuclear matrix proteins. *Cancer Res.*, 56: 1690-1694, 1996.
8. Keese, S. K., Meneghini, M. D., Szaro, R. P., and Wu, Y.-J. Nuclear matrix proteins in human colon cancer. *Proc. Natl. Acad. Sci. USA*, 91: 1913-1916, 1994.
9. Donat, T. L., Sakr, W., Lehr, J. E., and Pienta, K. J. Unique nuclear matrix protein alterations in head and neck squamous cell carcinomas: intermediate biomarker candidates. *Otolaryngol. Head Neck Surg.*, 114: 387-393, 1996.
10. Partin, A. W., Getzenberg, R. H., Carmichael, M. J., Vindivich, D., Yoo, J., Epstein, J. I., and Coffey, D. S. Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. *Cancer Res.*, 53: 744-746, 1993.
11. Khanuja, P. S., Lehr, J. E., Soule, H. D., Gehani, S. K., Noto, A. C., Choudhury, S., Chen, R., and Pienta, K. J. Nuclear matrix proteins in normal and breast cancer cells. *Cancer Res.*, 53: 3394-3398, 1993.
12. Konety, B. R., and Getzenberg, R. H. Nuclear structural proteins as biomarkers of cancer. *J. Cell. Biochem. Suppl.*, 32/33: 183-191, 1999.

<sup>5</sup> S. Oesterreich, unpublished results.

13. Keese, S. K., Briggman, J. V., Thill, G., and Wu, Y.-J. Utilization of nuclear matrix proteins for cancer diagnosis. *Crit. Rev. Eukaryotic Gene Expression*, 6: 189-214, 1996.
14. Getzenberg, R. H., and Coffey, D. S. Tissue specificity of the hormonal response in sex accessory tissues is associated with nuclear matrix protein patterns. *Mol. Endocrinol.*, 4: 1336-1342, 1990.
15. Getzenberg, R., Pienta, K., and Coffey, D. The tissue matrix-cell dynamics and hormone action. *Endocr. Rev.*, 11: 399-417, 1990.
16. Rue, M., Dunn, R., and Ruh, T. Interrelationships between nuclear structure and ligand-activated intracellular receptors. *Crit. Rev. Eukaryotic Gene Expression*, 62: 271-283, 1996.
17. Barrack, E. R., and Coffey, D. S. The specific binding of estrogens and androgens to the nuclear matrix of sex hormone responsive tissues. *J. Biol. Chem.*, 255: 7265-7275, 1980.
18. Barrack, E. R., and Coffey, D. S. Biological properties of the nuclear matrix: steroid hormone binding. *Recent Prog. Horm. Res.*, 38: 133-195, 1982.
19. Barrett, T. J., and Spelsberg, T. C. Nuclear matrix and steroid hormone action. *Vitam. Horm.*, 55: 127-163, 1999.
20. Eggert, M., Michel, J., Schneider, S., Bornfleth, H., Baniahmad, A., Fackelmayer, F., Schmidt, S., and Renkawitz, R. The glucocorticoid receptor is associated with the RNA-binding nuclear matrix protein hnRNP U. *J. Biol. Chem.*, 272: 28471-28478, 1997.
21. Oesterreich, S., Zhang, Q., Hopp, T., Fuqua, S., Michaelis, M., Zhao, H., Davie, J. R., Osborne, V. K., and Lee, A. V. Tamoxifen bound estrogen receptor strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. *Mol. Endocrinol.*, 14: 369-381, 2000.
22. Montano, M. M., Ekena, K., Delage-Mourroux, R., Chang, W., Martini, P., and Katzenellenbogen, B. S. An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. *Proc. Natl. Acad. Sci. USA*, 96: 6947-6952, 1999.
23. Chen, J. D., and Evans, R. M. A transcriptional co-repressor that interacts with nuclear hormone receptors. *Nature (Lond.)*, 5: 454-457, 1995.
24. Sande, S., and Privalsky, M. L. Identification of TRACs (T3 receptor-associating cofactors), a family of cofactors that associate with, and modulate the activity of, nuclear hormone receptors. *Mol. Endocrinol.*, 10: 813-825, 1996.
25. Heinzel, T., Lavinsky, R., Mullen, T.-M., Soderstrom, M., Laherty, C., Torchia, J., Yang, W.-M., Brard, G., Ngo, S., Davie, J., Seto, E., Eisenman, R., Rose, D., Glass, C., and Rosenfeld, M. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. *Nature (Lond.)*, 387: 43-48, 1997.
26. Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S. C., Heyman, R. A., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. *Cell*, 85: 403-414, 1996.
27. Onate, S. A., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. *Science (Washington DC)*, 270: 1354-1357, 1995.
28. Lee, S. K., Kim, H. J., Na, S. Y., Kim, T. S., Choi, H. S., Im, S. Y., and Lee, J. W. Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits. *J. Biol. Chem.*, 273: 16651-16654, 1998.
29. Na, S. Y., Lee, S. K., Han, S. J., Choi, H. S., Im, S. Y., and Lee, J. W. Steroid receptor coactivator-1 interacts with the p50 subunit and coactivates nuclear factor  $\kappa$ B-mediated transactivations. *J. Biol. Chem.*, 273: 10831-10834, 1998.
30. Torchia, J., Rose, D. W., Inostroza, J., Kamei, Y., Westin, S., Glass, C. K., and Rosenfeld, M. G. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function [see comments]. *Nature (Lond.)*, 387: 677-684, 1997.
31. Lee, S. K., Kim, H. J., Kim, J. W., and Lee, J. W. Steroid receptor coactivator-1 and its family members differentially regulate transactivation by the tumor suppressor protein p53. *Mol. Endocrinol.*, 13: 1924-1933, 1999.
32. Oesterreich, S., Weng, C.-N., Qiu, M., Hilsenbeck, S. G., Osborne, C. K., and Fuqua, S. A. W. The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. *Cancer Res.*, 53: 4443-4448, 1993.
33. Laborda, J. 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. *Nucleic Acids Res.*, 19: 3998, 1991.
34. Gossen, M., Freundlieb, S., Bender, G., Mueller, G., Hillen, W., and Bujard, H. Transcriptional activation by tetracyclines in mammalian cells. *Science (Washington DC)*, 268: 1766-1769, 1995.
35. Wenger, C. R., Beardslee, S., Owens, M. A., Pounds, G., Oldaker, T., Vendelay, P., Pandian, M. R., Harrington, D., Clarke, G. M., and McGuire, W. L. DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. *Breast Cancer Res. Treat.*, 28: 9-20, 1993.
36. Lee, A. V., Weng, C. N., Jackson, J. G., and Yee, D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. *J. Endocrinol.*, 152: 39-47, 1997.
37. Gossen, M., and Bujard, H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. *Proc. Natl. Acad. Sci. USA*, 89: 5547-5555, 1992.
38. Chen, P. L., Scully, P., Shew, J. Y., Wang, J. Y., and Lee, W. H. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. *Cell*, 58: 1193-1198, 1989.
39. Bullions, L. C., Notterman, D. A., Chung, L. S., and Levine, A. J. Expression of wild-type  $\alpha$ -catenin protein in cells with a mutant  $\alpha$ -catenin gene restores both growth regulation and tumor suppressor activities. *Mol. Cell. Biol.*, 17: 4501-4508, 1997.
40. Moretti-Rojas, I., Fuqua, S. A., Montgomery, R. A. D., and McGuire, W. L. A cDNA for the estradiol-regulated 24K protein: control of mRNA levels in MCF-7 cells. *Breast Cancer Res. Treat.*, 11: 155-163, 1988.
41. Fan, S., Wang, J.-A., Yuan, R., Ma, Y., Meng, Q., Erdos, M. R., Pestell, R. G., Yuan, F., Auborn, K. J., Goldberg, I. D., and Rosen, E. M. BRCA1 inhibition of estrogen receptor signaling in transfected cells. *Science (Washington DC)*, 284: 1354-1356, 1999.
42. Prall, O. W., Rogan, E. M., and Sutherland, R. L. Estrogen regulation of cell cycle progression in breast cancer cells. *J. Steroid Biochem. Mol. Biol.*, 65: 169-174, 1998.
43. Kleiman, F. E., and Manley, J. L. Functional interaction of BRCA1-associated BARD1 with polyadenylation factor CstF-50. *Science (Washington DC)*, 285: 1576-1579, 1999.
44. Tatsuka, M., Katayama, H., Ota, T., Tanaka, T., Odashima, S., Suzuki, F., and Terada, Y. Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. *Cancer Res.*, 58: 4811-4816, 1998.
45. Sen, S. Aneuploidy and Cancer. *Curr. Opin. Oncol.*, 12: 82-88, 2000.